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I. INTRODUCTION 
I.A. Background 
Mercury, a metal with no known physiological function, produces toxic effects in 
both the central nervous system (CNS) and peripheral nervous system (PNS). Figure 1 
depicts the various effects mercury has on cellular function. 
DNA 
(Damage, Mutation, 
Synthesis, etc.) 
N europrotective Defenses 
(Superoxide Dismutase, 
Glutathione, Catalase) 
Figure 1: Diagram of the physiological components mercury is known to affect 
The risk of low-level exposure to mercury is a very realistic threat since mercury exists in 
the environment in multiple forms, including trace metals as well as various 
pharmaceuticals, such as diuretics, antiseptics and skin preparations (U.S. Public Health, 
1989). With its specificity for cerebellar granule cells (Fonfria et al., 2001 ), mercurials 
interact with various CNS components, altering the intracellular calcium concentrations 
(Ca2+) and protein phosphorylation processes, both of which cause damage to the cells of 
the CNS. Mercury can interfere with synaptic transmission through effects on 
neurotransmitters, neurotransmitter receptors and the neuronal membrane. The clinical 
symptoms of mercury toxicity suggest the involvement of several motor, sensory, and 
cortical neuropathies. 
The toxicity of mercury is due, in part, to its oxidative properties. Since 
preceding research has shown that mercury generates reactive oxygen species and lipid 
peroxidation in brain tissues (Lee, et al., 200 I), it can be concluded that the resulting 
oxidative stress may contribute to the development of neurodegenerative disorders caused 
by mercury intoxication (Hussain, et al., 1997). Oxidative stress induced by the divalent 
mercury ion (Hg2+) increases the phosphorylation of tau protein in neuroblastoma cells 
(Olivieri et al., 2000), which is a common characteristic in patients suffering from 
Alzheimer's disease (AD). Perhaps this toxic metal represents an unexplored 
environmental factor that initiates a pathogenic cascade, resulting in CNS defects related 
to AD. The oxidative stress caused by low-level mercury concentrations over long 
periods of time may increase an individual's susceptibility to certain neurodegenerative 
diseases, like Alzheimer's disease. 
Chelation therapy is a common treatment for metal-induced pathologies. 
Chelation is defined as the formation of a metal ion complex in which the metal ion is 
associated with a charged or uncharged electron donor referred to as a ligand (Goyer, 
1991 ). At present, succimer is the chelation treatment used for acute mercury exposure 
(Dart, 2000). However it remains unclear as to whether the observed increase in mercury 
output upon treatment is a result of chelation action in the CNS. Dimercaptopropane 
sulfonic acid or 2,3-dimercapto-propane sulfonate (DMPS) has been found to remove 
extracellular mercury, but due to its non-Iipophilic properties, this chelating agent is 
unable to penetrate tissues to bind and remove mercury (Goyer, 1991 ). While research 
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has demonstrated that administration of this compound to patients with chronic mercury 
exposure yielded an increase in urinary mercury levels (Godfrey et al., 2003). CHEMET® 
(succimer .. 100mg capsule, NDA#Ol 9998) manufactured by Ovation Pharmaceuticals has 
been approved by the FDA and is available by prescription. In addition to the possible 
safety concerns and risk factors that prevent its approved usage, there is again no 
evidence that DMPS targets mercury in the CNS. While the pursuit for a treatment that 
focuses on the removal of mercury localized in the CNS continues, it is important to 
investigate both the concentration- and time-dependent effects this metal may exert on 
neurons represe~tative of the areas in the CNS predisposed to mercury-induced 
neurotoxicity. · 
I B. Signfficance/Objective of Study 
Due to the fact that the bulk of previous research has focused on acute exposure, 
the purpose of this project was to examine the functional, cellular and pharmacological 
changes that occurred upon exposing neuronal cells to low-level mercury concentrations. 
The rationale for low-level toxin exposure was to define better the intermediary changes 
that may lead to loss of cell function because previous work has shown that in the 
progressive stages of neurotoxic disease, biochemical events usually precede structural 
changes and permanent nervous system lesions or dysfunction (Manzo, et al., 1996). 
Lower concentrations of a toxicant may initiate subtle changes in cellular function .. which 
gradually gives way to cell dysfunction and/or death. It has been suggested that 
sequential measurements of neurochemical biomarkers may be useful to assess end points 
indicative of early manifestations oflater-developing toxicity .. recovery processes or 
adaptive changes during chronic exposure (Manzo, et a)., 1996). The goal of this work is 
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to pinpoint how mercury alters normal cellular mechanisms, ultimately leading to cell 
death, which is seen with acute exposure. 
Although clinical diagnosis and proof of chronic low-level mercury toxicity has 
been difficult to characterize due to the non-specific nature of the symptoms and signs 
(Godfrey et al., 2003), investigations of both the in vivo and in vitro effects upon mercury 
ex po sure have endeavored to identify possible biomarkers so as to prevent debilitating 
neurological long-term effects. The relevance of this work corresponds to the plethora of 
environmental mercury sources and the threat of covert exposure to a multi-faceted 
toxicant. 
The dopaminergic system was the focus of this study since symptoms of mercury 
toxicity, such as sensory, cognitive and motor malfunctions, closely resemble symptoms 
of a dysfunctional dopamine system. Neurological diseases like Alzheimer's, 
Parkinson's and schizophrenia would fall into this category of dopaminergic dysfunction. 
Dopamine uptake was examined as an index of toxicity because the metabolism of excess 
dopamine in the synapse results in an increased production of reactive oxygen species. 
The SK-N-SH cell line was utilized to study mercury toxicity because of its similarity to 
dopaminergic neurons in the substantia nigra and therefore reflect what is to be expected 
with in vivo studies. Functional studies were performed to explore changes in dopamine 
uptake when cells were treated with mercury. Cell viability and mode of cell death was 
examined to understand better necrotic and apoptotic mechanisms. Pharmacological 
concerns were addressed by measuring both transporter affinity and density to determine 
how mercury may alter the efficiency of the transporter as well as its ability to upregulate 
or downregulate the number of transporters in the cells. Evaluating the effects of low 
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levels of mercury will best mimic 'natural' mercury exposure in the environment and 
may shed light on a possible role for mercury in the progression ofneurodegenerative 
diseases. 
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II. LITERATURE REVIEW 
II.A. SK-N-SH Cell Line 
The SK-N-SH cell line, developed by J. L. Biedler, originated from the cells of a 
metastatic site in the brain of a 4-year-old female with bone marrow neuroblastoma 
(A TCC www.atcc.org). These cells have been used as a target cell line for induced 
cytotoxic studies. Researchers have found these particular cells to be noradrenergic in 
nature (Richards and Sadee, 1986), supporting the potential bioactivity of the 
neurotransmitters dopamine (DA) and norepinephrine (NE). Although it has not been 
officially reported that the SK-N-SH cell line specifically expresses dopamine 
transporters (DAT), previous studies have demonstrated that both DA and NE accumulate 
through a single competitive, saturable and active transport process (Richards and Sadee, 
1986). Active transport is indeed both sodium- and temperature-dependent (Richards and 
Sadee, 1986). While the SK-N-SH cell line has been described as neuronal-like cells 
with the ability to produce DA and NE, these cells were found to produce larger amounts 
of DA than NE (Richards and Sadee, 1986). The work of Liu and colleagues (2001) 
revealed that the viability of SK-N-SH cells has been linked to dopamine-induced 
cytotoxicity, which could be due to neuronal cells' increased sensitivity to DA 
neurotoxicity, the mechanism of antioxidants, as well as receptor-mediated signal 
transduction. These cells are routinely used in studies as a model of neurotoxicity as a 
consequence of the cell line expressing a means for both noradrenergic and dopaminergic 
transport. Therefore, the SK-N-SH cell line was utilized as our model system to examine 
mercury toxicity due to their similarity to dopaminergic neurons in the substantia nigra 
and therefore reflect what is to be expected with in vivo studies. 
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11.B. Dopamine Transporter (DAT) Pharmacology 
The dopamine transporter consists of twelve transmembrane spanning regions, 
with a large glycosyiated extracellular loop between regions III and IV (Figure 2). 
1NTAANEUftQNAL 
Figure 2: Sche111atic representation of the amino acid sequence from the rat dop~ine 
transporter. I through XII denote transmembrane spanning regions, (-SH) symbolize 
suggested localization of cysteine groups and w signify glycolsylation sites. (Schweri, 
1994) ' 
The mechanism of transport for the DAT, including the direction and magnitude, is 
dependent on membrane potential and the sodium- (Na+) and chloride- (Cr) ion gradients 
(F alkenburger, et al., 200 I). Located on the presynaptic terminal, the DAT represents a 
major mechanism for the inactivation of DA transmission at the synapse, thus serving a 
pivotal role in the regulation of DA levels in the central nervous system (Jiao~ et al., 
2003 ). Although the primary function of DAT is to move dopamine from the synaptic 
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space into the neuron, there is also evidence that the DA transporter can cause dopamine 
to be released from the pre-synaptic cell in dendritic-dendritic exchanges within the 
substantia nigra (Loupe, et al., 2002), leading to excess synaptic DA. 
In an attempt to characterize the DAT, previous research has examined the 
number of binding sites, conformations of the transporter, and the interaction of different 
ligands. Earlier work has not been able to confirm whether the DAT has one or two 
binding sites (Dersch~ et al., 1994). However, since DAT has high-affinity binding sites 
that are triggered at the low extracellular DA concentration such that DAT can 
accomplish its normal uptake function, the intracellular and extracellular balance of 
neurotransmitter is maintained (Liu, et al., 2001 ). Although both the dopamine and 
norepinephrine transporters (DAT and NET) can effectively transport each other"s 
substrates, NET transports dopamine and norepinephrine with similar affinity (Km of 
approximately 1 µM) values, whereas the DAT displays a 10-fold higher affinity for 
dopamine over norepinephrine (Giros, et al., 1994). It is important to note that the DA 
recognition site on the DAT (where DA binds) can· face the inner or outer surface of the 
membrane, with the direction of DA transport being dependent on which way the 
recognition site is facing (Eshleman, et al., 1994 ). Damage to the membrane, including 
lipid peroxidation., protein oxidation and other effects of oxidative stress, can also change 
the conformation of the DAT protein (Wu, et al., 1997), creating a nonfunctional 
transporter. Certain drugs also have a high affinity for DAT binding sites and once 
bound, they can modulate synaptic DA concentrations through a number of different 
actions. The drug can compete with other ligands, including DA, for the binding site, act 
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as a substrate and in turn increase the release of DA, or completely block the transporter, 
inhibiting the reuptake mechanism. 
In addition to preventing DA reuptake, blocking the DAT prohibits the dendritic 
release of dopamine and self-inhibition of the neuron (Falkenburger, et al., 2001). The 
work of Dersch and associates (1994) suggests that the binding sites for various ligands 
may have overlapping domains of the DA uptake inhibitor recognition site. Due to the 
possibility of indistinct binding domains, it remains unclear whether different DA uptake 
blockers bind to one and the same domain on the DAT or to different domains (Wu, et 
al., 1997). This uncertainty may account for the potency of various drugs, effects on 
different neurotransmitters as well as other elicited responses. Potential conformational 
changes to the transporter can also change the activity of certain DAT inhibitors 
(Eshleman, et al., 1994). For example, an inhibitory drug has a higher affinity for the 
outward facing site. Once the drug binds, the equilibrium shifts to the outward facing 
site, preventing DA release through the DAT. When the outward-facing site is blocked 
by the bound ligand; nothing can get into the cell via the transporter and due to the effects 
of the bound ligand, nothing can get out of the cell by way of the transporter, resulting in 
complete inactivation of DAT. 
The function of the DAT has been linked to apoptosis. It has been suggested that 
the DAT mediates a dopamine-dependent apoptotic signal transduction pathway that is 
independent of dopamine uptake into the cell (Liu, et al., 2001 ). High extracellular 
concentrations of DA can activate the low-affinity binding sites on the transporter, 
stimulating a similar signal transduction pathway, again triggering apoptotic processes 
(Liu, et al., 2001 ). In order to attenuate this phenomenon, administration of a compound 
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that stimulates DA uptake would reduce extracellular DA concentrations and could 
therefore prevent apoptotic signal transduction pathways. 
JI. C. Nm·epinephrine Transporter (NET) Pharmacology 
Like the DAT, the NET also consists of twelve transmembrane spanning regions 
with both the amino and carboxyl tenninals positioned in the cytosol. As a member of 
the monoamine transporter family, activity of NET is dependent on the Na+/cr gradient. 
However .. previous research has uncovered data that suggest NET is less vulnerable to 
inactivation by oxidative stress than other Na+ /Cr dependent transporters (Fleckenstein, 
et al., 2000). Perhaps the difference in transporter activity when subjected to oxidative 
free radicals may be related to the uptake mechanism and regulation of the NET. 
The primary function of NET is to terminate transmission of norepinephrine by 
definition (Zhu, et al., 2000). Although it is not NET's principal substrate, there is some 
evidence of that extracellular dopamine can be regulated by the NET (Yamamoto and 
Novotney, 1998). NET activity is inhibited by antidepressants, such as desipramine and 
reboxetine (Weinshenker, et al., 2002) and psychostimulants, like cocaine and 
amphetamine (Zhu, et al., 2000). By blocking the transporter, NE accumulates in the 
synapse. Norepinephrine signaling modulates a plethora of neurological functions 
including attention, mood, arousal, learning and memory (Schwartz, et al., 2003) as well 
as being involved in cardiovascular function, metabolism, embryonic development, 
susceptibility to seizure, maternal behavior and response to drugs of abuse (Weinshenker, 
et al., 2002). In fact, Boschmann and colleagues (2002) concluded that norepinephrine 
release from postganglionic adrenergic neurons has a central role in the regulation of 
energy metabolism and blood pressure. Thus, compounds that modulate norepinephrine 
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uptake can change or interfere with the connection between the transmitter and its effects 
throughout the body. 
The NET is regulated by neuronal activity, neurotransmitters, peptide hormones 
and second messengers (Apparsundaram, et al., 2001), such as protein kinase C (PKC), 
cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP) and 
nitric oxide (NO). For example, NET protein levels have been reported to be 
downregulated by G protein-coupled receptors linked to protein kinase C 
(Apparsundaram, et al., 200 I). PKC regulation begins through G protein-coupled 
pathways, where adenylate cyclase and phospholipase C (PLC) are activated. Increased 
levels of PLC lead to increased amounts of inositol phosphates and diacylglycerol 
(DAG). The elevation of inositol phosphates causes Ca++ -dependent activation of PKC 
(Apparsundaram, et aL, 1998), which ultimately affects the number of norepinephrine 
transporter proteins. Recalling the systems linked to norepinephrine, it is not surprising 
that the regulation and expression of the NET protein has been linked to the development 
of psychiatric illnesses, such as depression (Zhu, et al., 2000), post traumatic stress 
syndrome and attention deficit disorder (Schwartz, et al., 2003). The work of 
Apparsundaram and associates (200 I) found that impaired NET function or expression 
has been reported in cardiac failure, diabetic cardiomyopathy and hypertension, 
establishing a link between norepinephrine transport and disease. 
11.D. Dopamine Uptake Inhibitors: GBR-12909 and Mazindol 
In order to evaluate the relative extent of catecholamine uptake, selective and 
nonselective transport inhibitors are used to differentiate pharmacologically between 
dopamine transport through DAT and NET. If a selective drug preferentially targets one 
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of the transporter systems, a nonselective drug can be utilized to determine the amount of 
catecholamine uptake through the other transporter system. Fractional occupancy, a term 
used to relate the nwnber of occupied receptor sites and the concentration of ligand 
(Hodgson and Smart, 2001), can be used to calculate the density of transport sites 
inhibited in functional assays. 
1-[2[bis ( 4-fluorophenyl)] ethyl] 4-(3-phenyl propenyl)-piperazine (Hosli and 
Hosli, 1997), commonly termed GBR-12909, was used in the uptake studies due to its 
selectivity for the dopamine transporter. According to Elmer and collaborators (1996), 
G BR-12909 has a Ki of 3. 7 nM for the dopamine transporter, which means this 
concentration of GBR-12909 inhibited 50% of dopamine uptake in comparison to control 
values, taking into account the affinity of GBR-12909 for the DAT. This drug selectively 
inhibits the uptake of dopamine with a 100-fold lower affinity for norepinephrine uptake 
inhibition (Hosli and Hosli, 1997). The in vivo and in vitro differences in the ability of 
GBR-12909 to 'successfully' block dopamine uptake by inhibiting the transporter is 
dependent on its phannacokinetic properties such as permeability to the blood-brain 
barrier, metabolism, or protein binding (Kimura, et al., 2003). The research performed 
by Loupe and associates (2002) determined that GBR-12909 is a highly selective 
dopamine re-uptake blocker that by inhibiting presynaptic dopamine reuptake, makes 
dopamine more available at post-synaptic receptor sites. Kimura and colleagues (2003) 
confirmed that extracellular dopamine levels increased after GBR-12909 is administered 
when compared to control values. 
Since GBR-12909 preferably inhibits uptake at the DAT more than the NET, 
another nonselective inhibitor was chosen for use in functional assays to account for the 
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dopamine being taken up by NET. The work of Richards and Sadee ( 1986) showed that 
mazindol inhibits dopamine accumulation in SK-N-SH cells. Although [3H] mazindol 
has been reported to label both dopamine and norepinephrine uptake sites and block both 
DA and NE transporters (Eshleman, et al., 1994; Richards and Sadee, 1986), a greater 
concentration of extracellular dopamine was measured when using GBR-12909 
compared to using mazindol (Loupe, et al., 2002). According to the work of Nakachl and 
collaborators ( 1995), the physiological use of dopamine uptake inhibitors like mazindol 
and GBR-12909 are to enhance dopaminergic neurotransmission in the central nervous 
system through an increase in dopamine concentration in the synaptic cleft as the result of 
reuptake inhibition at nerve tenninals. For the functional studies employed in this 
project, both the selectivity and inhibitory activity of these drugs can be exploited in 
order to identify the transport system as well as quantify the amount of dopamine being 
taken back into the cells. Mazindol, reported to be a non-addictive dopamine uptake 
inhibitor of moderate potency, has a Ki value of 38.0 nM (Elmer, et al., 1996) for the 
dopamine transporter. The larger Ki value signifies that greater concentrations of 
mazindol are required to achieve 50% inhibition of dopamine uptake. For these studies, a 
concentration of I µM mazindol will inhibit DA uptake through the DAT or NET greater 
than 95% occupancy allowing for mazindol to be used to define nonspecific uptake. 
/I.E. Neurotoxicity: Focus on the Dopaminergic System 
Within the nervous system, there are a number of molecular targets for toxicity 
including membrane-bound receptors, enzymes responsible for synthesis and degradation 
of neurotransmitters, second messengers and high-affinity uptake systems (Manzo, et al., 
1996). With respect to the dopaminergic system, all five dopamine receptor subtypes 
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(Dl-05), classified as DI- or D2-like, as well as the dopamine transporter, the primary 
uptake mechanism for DA, are membrane-bound macromolecules (Siegel, et al., 1999). 
As a part of the biosynthetic pathway for catecholamines (Figure 3 ), the synthesis of 
dopamine and further synthesis of norepinephrine and epinephrine are dependent on 
specific enzymes and cofactors. 
L-Tyrosine 
• L-DOPA 
l 
Dopamine 
l 
N orepinephrine 
l 
Epinephrine 
Tyrosine hydroxylase 
[Biopterin, 0 2] 
DOPA decarboxy lase 
[Pyridoxal phosphate] 
Dopamine ~-hydroxylase 
[ 0 2, Ascorbate] 
Phenylethanolamine 
N-methyltransferase 
[S-adenosylmethionine] 
Figure 3: Simplified flowchart depicting the various steps in the pathway for 
catecholamine synthesis. Enzymes responsible for conversion to the next step of the 
pathway are shown to the right. Substrates and cofactors required for each conversion 
process are listed in square brackets. (Siegel, et al., 1999) 
Tyrosine hydroxylase uses molecular oxygen and biopterin to convert tyrosine to 3,4-
dihydroxy-L -phenylalanine (L -DOPA) (Siegel, et al., 1999). This product is then 
converted to dopamine, the final step of the pathway in dopaminergic neurons, by way of 
the enzyme DOPA decarboxylase and its coenzyme pyridoxal phosphate (Siegel. et al... 
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1999). In non-dopaminergic neurons, dopamine ~-hydroxylase, in conjunction with 
molecular oxygen and ascorbate, changes dopamine to norepinephrine, which can then 
further be synthesized to epinephrine by phenylethanolamine N-methyltransferase and S-
adenosylmethionine (Siegel, et al., 1999). Monoamine oxidase (MAO), an enzyme 
responsible for deamination .. inactivates catecholamines by converting them to their 
respective aldehyde (Siegel, et al." 1999). According to the research done by Manzo and 
colleagues ( 1996), neuronal second messenger systems such as intracellular calcium ion, 
adenylyl cyclase, guanylyl cyclase, phosphoinositides, cAMP-dependent protein kinase 
and protein kinase C can be affected by submicromolar concentrations of mercury. This 
same work contends that changes to second messenger systems may create biological 
""factors", which in tum regulate the long-term responses to toxic substances acting on 
that system (Manzo, et al., 1996). Identification and measurement of these factors could 
help to predict the consequences of chronic exposure to mercury. 
The dopaminergic system is rooted in the basal ganglia. This portion of the brain 
is linked to cortical, thalamic, sensory and motor function and regulated by various 
neurotransmitters, including dopamine, norepinephrine, serotonin, glutamate, aspartate, 
acetylcholine, and gamma-aminobutyric acid (GABA) (Siegel, et al., 1999). The 
dopaminergic neurons of the substantia nigra innervate the striatum, making them the 
most important modulators of basal ganglia function (Falkenburger, et al., 2001; Siegel, 
et al., 1999). Currently, serum levels of dopamine ~-hydroxylase and monoamine 
oxidase type Bare being used as biomarkers to gauge dopaminergic function (Manzo, et 
al., 1996). 
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11. F. The Histo,y of Mercury: Different Forms in the Environment and Early Uses . 
Mercury exhibits toxicity in the central and peripheral nervous systems, as well as 
in other organ systems. The general population is constantly subjected to exposure to 
various forms of mercury .. including organic mercury, inorganic mercurial salts, and 
elemental mercury in the form of mercury vapor. Methylmercury, a form of organic 
mercury .. tends to bioaccumulate in the food chain (Tchounwou, et al., 2003 ), especially 
in fish. Organic mercury can be absorbed through the lungs or gastrointestinal (GI) tract, 
as well as through the skin in some cases (Gochfeld, 2003). Inorganic forms of mercury 
are extremely potent enzyme inactivators (Godfrey, et al., 2003), disrupting numerous 
enzymatic reactions. The different forms of inorganic mercury vary in solubility and 
adsorptivity (Gochfeld, 2003)" and therefore in potency and intrinsic activity. Common 
inorganic salts include: mercuric chloride (HgCb) which is used in certain fungicides, 
mercurous chloride (Hg2Cli, also known as calomel) which has been used in medicine, 
mercuric fulminate (Hg(OCN)i) which is used as a detonator for explosives and mercuric 
sulfide (HgS .. also called vermillion) which is used as a high-grade paint pigment 
(Tchounwou, et al., 2003). Elemental mercury, also termed 'quicksilver', is readily 
volatilized (Gochfeld, 2003), producing mercury vapor. Mercury vapor, a common 
contaminant of industrial applications, has been found to be very toxic to the lungs and 
nervous system (Asano, et al., 2000). Researchers have also revealed that the natural 
deterioration of mercury-containing dental amalgams can lead to mercury vapor 
production (Godfrey, et al., 2003). The risk oflow-level exposure to mercury is a serious 
threat due to environmental contamination as a result of mining, smelting, and industrial 
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discharge including ingestion via inhalation and the food chain (Stohs and Bagchi, 19.95), 
as well as commercial, medicinal, and agricultural usage. 
While society may not have been aware of mercury's toxic effects at the time, use 
of this metal has been dated back as early as the 15th or 16th century (Asano, et al., 2000). 
Mercury is a naturally occurring trace metal found in the earth's crust, mainly in sulfide 
ores .. such as cinnabar (Kazantis, 2002). Besides the mining of such ores, additional 
mercury can be released into the environment by way of erosion and volcanic eruption 
(Tchounwou .. et al. .. 2003). Mercury has also been used to extract gold from its ores 
(Kazantis .. 2002), creating yet another potential exposure route. Industrial use for 
mercury has included lamps, measurement, medical instruments as well as a mildew-
proofing agent for paints (Kazantis, 2002). 
At one time, industrial mercury discharge into waterways was commonplace 
because people believed that mercury sank to the bottom and bound to the sediment, 
producing no harmful effects (Tchounwou, et al., 2003); unfortunately they were very 
wrong. In the l 950's, the first major mercury outbreak of mercury poisoning (in the form 
of methylmercury) occurred in Minimata, Japan where local industrial discharge created 
mercury-polluted waters and people were contaminated by eating poisoned fish (Castoldi, 
et al... 2001 ). The chemical company responsible for this deadly pollution was not forced 
to curtail its mercury releases until 1968 (Gochfeld, 2003), allowing for the 
methyl mercury to make its way up through food chain to affect the health of innocent 
citizens. During the early 20th century, the fungicidal properties of mercurial compounds 
led to commercial agricultural applications (Tchounwou, et al., 2003). Mercury's use in 
both pesticides and fungicides afforded this toxic metal another entrance to both the food 
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chain and water supplies. Another significant mercury-poisoning incident took place in 
Iraq in the 1970's when people had eaten bread made from grain that had been treated 
with an organomercuric fungicide ( Castoldi, et al., 2001 ). 
In the realm of medicine, a type of inorganic mercury known as calomel (sweet 
mercury) was once commonly used to treat many ailments, including yellow fever, 
typhus and syphilis (Weinstein and Bernstein, 2003). In fact, it wasn't until the l 940's 
that people realized its toxicity when calomel-based teething powders caused a scourge of 
mercury poisoning called pink disease among infants and children (Weinstein and 
Bemstein'I 2003 ). At one point in time, different forms of mercury were used in 
cosmetic-based pharmaceutical products; ammoniated mercury in skin lightening creams 
and mercuric iodide in skin-lightening soaps (Kazantis, 2002). More recently, the 
American Academy of Family Physicians, the Advisory Committee on Immunization 
Practices and the U.S. Public Health Service have advised that thimerosal, a derivative of 
ethylmercury, should no longer be used as a vaccine preservative or biological agent for 
medical therapy (Tchounwou, et al., 2003). In response to the combination of a desire for 
health preservation and a growing knowledge of its toxic effects, scientists set out to 
investigate the different targets and mechanisms involved in mercury toxicity. 
/1. G. Toxic Action: Pathophysiological Effects Resulting from Mercury Exposure 
The toxicity of a metal is contingent upon several factors, including but not 
limited to: solubility, the ability to be absorbed and distributed into tissues, transport, 
chemical reactivity and complexes formed when the metal binds to certain biological 
molecules (Stohs and Bagchi, 1995). According to the work of Tchounwou and 
colleagues (2003 )'I mercury toxicity specifically depends on exposure route, frequency· 
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dose level.. nutritional status, individual susceptibility and genetic disposition. Though 
they may have different mechanisms of action, inorganic and organic forms of mercury 
exhibit a wide range of toxic properties including nephrotoxicity, neurotoxicity and 
gastrointestinal toxicity with ulceration as well as hemorrhage (Frisk, et al., 2000). 
Studies have shown that inorganic mercury causes toxicity in the kidney; the 
proximal convoluted tubule being the main target for damage in response to acute 
exposure (Rodilla., et al., 1998). The inorganic form of mercury quickly induces 
nephrotoxicity as the mercuric salts accumulate rapidly in the kidneys, producing acute 
tubular necrosis within hours of administration (Rodilla, et al., 1998). According to the 
work of Aleo and collaborators (2002), a possible mechanism in which mercury causes 
nephrotoxicity is via the biochemical damage of mitochondrial function and calcium 
metabolism as well as immune mechanism. 
Exposure to mercury is known to elicit neurotoxic consequences, although the 
pathogenesis of mercury toxicity depends on several factors, including the chemical form 
of mercury., and the developmental period at which intoxication occurs (Monnet-Tschudi, 
et al. .. 1996). The research ofTchounwou and associates (2003) found that mercury 
damages DNA., impairs mitosis, and disrupts neuronal migration, which iJJustrates how 
mercury can be especially damaging to a developing child. Previous work has examined 
the symptoms and general pathology of mercury toxicity with long- and short-term 
exposures. Mattingly and colleagues (2001) found that human exposure to moderate 
levels of mercury can cause neurotoxic manifestations, including sensory, cognitive and 
motor abnormalities. Long-term effects of mercury neurotoxicity include central hearing 
loss., vestibular dysfunction, poor concentration, mental deterioration, speech difficulty, 
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chronic headaches .. impaired vision, autism, chronic fatigue, weakness of extremities, 
insomnia .. ataxia~ tremor, delirium and rigidity (Asano, et al., 2000; Godfrey, et al., 2003; 
Gopal. 2003). In addition to defects in the CNS, mercury exposure has also been 
associated with erythrism, arrhythmias and cardiomyopathy (Tchounwou, et al., 2003). 
Though lower concentrations of mercury may have delayed cytotoxic effects, the 
presence of mercury may still interfere with signal transduction and stimulate protein 
tyrosine phosphorylation (McCabe, et al., 1999) as well as reduce DNA synthesis. Even 
short-term. low-concentration exposure to mercury indicate that mercuric chloride 
increases post-transcriptional elevation of protein and intracellular Ca2+ concentrations, 
as well as oxidative phosphorylation in the mitochondria (Rao, et al., 2001 ). 
According to the work of Godfrey and associates (2003), mercury is very 
destructive at the mitochondrial level where catalase can demethylate organic mercury 
species into highly reactive inorganic mercury, which can then further damage to cellular 
function. The research done by Uversky, Li and Fink (2001) ascertained that metal-
induced oxidant stress can damage critical biological molecules and initiate a cascade of 
events including mitochondrial dysfunction, excitotoxicity, and a rise in cytosolic free 
calcium, leading to cell death. Mercury has been shown to disrupt cellular metabolism 
and activities through interaction with membrane proteins (Worth, et al., 200 I), resulting 
in membrane polarization and production of both nitric oxide (NO) and other reactive 
oxygen species (ROS). 
Generation of ROS propagates further damage to aspects of cellular function such 
as alteration to DNA, breakage of DNA strands, disruption of protein function, reduction 
of glutathione~ inhibition of glutathione synthesis, alteration in calcium homeostasis and 
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lipid peroxidation (Rao, et al., 2001; Stohs and Bagchi, 1995). In addition to increased 
ROS production~ exposure to mercury decreased the activity of superoxide dismutase 
(SOD) .. Cu/Zn-SOD and Mn-SOD (Hussain, et al., 1997), all of which are enzymes that 
serve as crucial antioxidant defenses. Mercury's ability to interact with the membrane 
can also lead to malfunctions with transporter proteins, inhibiting activity at the Na+ -K+ -
er co-transporter (Jacoby, et al., 1999). The variety of effects seen in mercury-induced 
neurotoxicity moved scientists' focus to mercury's mechanism of action in the central 
nervous system. 
II. H. localized Mechanism of Action: Mercury's Effects in the CNS 
Early studies in the CNS began to shed some light on the activity of mercury in 
the brain. Brookes ( 1988) found that mercury compounds inhibit amino acid transport. 
Mercury has also been shown to alter protein function due to interaction with sulthydryl 
groups (Jacoby, et al., 1999). Others determined that exposure to mercury predisposes 
affected cells to further damage from reactive oxygen species (Aleo, et al., 2002) brought 
on by oxidative stress. 
Mercury's mechanism of action begins with gaining access to the CNS, and 
exerting its toxic effects at certain receptors in specific brain regions, causing dysfunction 
in the sensitive balance of neurological systems. Mercury enters the CNS through a 
variety of different mechanisms. The brain's main defense mechanism against toxicants 
is the blood brain barrier (BBB). According to Zheng and colleagues (2003), a series of 
active or receptor-mediated transport systems inherent to the BBB vasculature serve to 
control the transport of metals into the brain. However, the permeability across the BBB 
is dependent upon the toxicant's lipophilicity and size (Zheng, et al., 2003), in this case 
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mercury. Organic mercury is more lipophilic, allowing it to easily diffuse across 
membranes. Mercury can also gain entry_ to the CNS via "piggy-back" transport due to 
its affinity for sulfl1ydryl groups; by forming complexes with molecules which already 
have well-established physiological transport systems, such as glutathione, methionine or 
cysteine (Hultberg. et al., 2001, Zheng, et al., 2003). Though most inorganic mercury 
salts are less toxic due to their decreased rate of transport across the BBB, certain 
inorganic mercury salts, like HgCh can act as a direct barrier toxicant (Zheng, et al., 
2003) or a choroid plexus toxicant (Zheng, 2001). 
Active defense systems located in the brain, like superoxide dismutase, 
glutathione peroxidase and catalase, work to prevent free radical-initiated oxidative stress 
(Zheng, et al., 2003). However, the effectiveness of the barrier systems may also be 
compromised either in pathological situations or following toxic insults by compounds 
that target the blood brain interface (Zheng, et al., 2003), such as heavy metals. The 
breakdown of said barriers, possibly caused by metal toxicity, can lead to the "leakage" 
of neural macromolecules and immune cells (Manzo, et al., 1996), allowing them to 
become more vulnerable to further damage by metal toxicants such as mercury. 
Earlier studies have suggested that mercury is taken up by microvesicles in 
neurosecretory terminals and conveyed to neuronal bodies by retrograde axonal transport 
(Villegas, et al., 1999). The research of Hare and associates (1990) determined that 
introduction of Hg2+ into the system increases the permeability of the plasma membrane 
to small molecules, enhancing the cellular injury sustained by such toxic action. Other 
work has shown that mercury deposits directly in the choroid plexus; causing damage to 
the structure itself as well as mediating entry for metals and other neuroactive toxicants 
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into brain tissues (Zheng, 2001 ). Due to the fact that mercury disrupts the normal 
function of ion channels (Asano, et al., 2000), this may serve as a means for mercury to 
gain access to brain tissue. Once the toxin has made its way into the cells, mercury can 
bind to a variety of enzyme systems producing non-specific cell injury or cell death 
(Frisk .. et al... 2000). 
Relatively low concentrations of mercury (1 - 1000 µM) can inhibit activity at 
muscarinic, nicotinic, NMDA, GABAA and dopamine receptors (Fonfria, et al., 2001). 
Mercury disturbs the activity of enzymes by binding to electron-rich sulfhydryls, 
carboxyls, and imidizoles (Kumar, et al., 2002) but has the highest affinity for sulfhydryl 
groups, which can be found in glutathione, metallothionine and cysteine. To a lesser 
degree, mercury has also been found to bind to hydroxyl, carboxyl and phosphoryl 
groups (Tchounwou, et al., 2003), all of which are imperative for protein function. 
Previous research has also uncovered mercury's ability to alter neuronal differentiation, 
which can affect the production of neurotransmitters and ultimately activate the apoptotic 
cascade (Rossi, et al.1997). The work of Faro, and others (2001) has indicated HgCh 
exerts a well-known inhibitory effect on membrane transport that is generally attributed 
to its high-affinity interaction with protein sulfhydryl groups. Mercury's reactivity at 
sulfbydryl and other electron-donating groups can cause protein unfolding (Brookes, 
1988), which can result in a breakage of the lipid bilayer membrane or disruption of 
membrane transporter function. The role of metallothionine in metabolism, transport, 
and homeostasis of metals determines whether the pathway leads to toxicity or 
detoxification (Rodilla, et al., 1998). Dithiols, another form of sulfhydryl group, enhance 
the toxic effects of mercury due to its inability to form stable complexes .. which releases 
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mercury ions .. allowing for direct mercury uptake into cells (Hultberg, et al., 2002). The 
work ofTchounwou and colleagues (2003) confirmed that divalent inorganic mercury 
(Hg2+) binds to multiple cell surface receptors via free sulfhydryl groups and results in 
nonspeci fie receptor clustering, dysregulated signal transduction, and disorders of cellular 
function. 
Due to its electrophilic nature, mercury can complex with DNA by binding to 
negatively charged sites~ altering base pairs and forming cross-linkages between strands, 
resulting in mutagenesis (Rao, et al., 2001), which can lead to the production of 
dysfunctional proteins. Mercury can also interfere with protein production and DNA 
synthesis by binding to the sulfhydryl groups contained in the amino acid sequences that 
make up proteins associated with replication (Rao, et al., 2001), ultimately distorting the 
genetic information so that the affected cell cannot maintain normal function. 
Furthermore, prior work has shown that mercury can bind to the electron-rich bases of 
mitochondrial DNA (Bhattacharya, et al., 1997), causing mutation, fragmentation and 
eventual degradation of DNA, rendering afflicted mitochondria useless. 
11.l Targeted Brain Regions 
There are several factors that determine what regions of the brain are affected by 
the toxic actions of mercury. Areas of the brain affected may be defined by transport 
efficiency (Brookes., 1988); the more efficient the transport systems, the more likely 
mercury will gain entry to initiate its toxic effects. Prior work has also suggested that 
mercury has achieved access to striatal tissue (Faro, et al., 2001 ), due to the increased 
levels of dopamine detected when exposed to mercury (HgCh). 
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One specific cell type in the brain that seems to be targeted by mercury toxicity is 
microglia. According to the work of Monnet-Tschudi and associates ( 1996), even at sub-
cytotoxic concentrations distinct glia-specific reactions could be observed with both 
organic and inorganic mercury compounds. Microglial cells have proven to be extremely 
sensitive to the toxic effects of mercury, exhibiting damage before any sign of neuronal 
degeneration in multiple brain regions (Monnet-Tschudi, et al., 1996). When microglia 
are activated by neuronal insult resulting in inflammation, the release of superoxide anion 
CO2-), hydrogen peroxide (H20 2), and nitric oxide (NO) is increased, further contributing 
to oxidative neurotoxicity (Wang, et al., 2003). The presence of these free radicals 
allows for the formation of peroxynitrite (ONOO), a highly reactive free radical which 
damages lipids, membranes, proteins, DNA and sulfhydryls, as well as inactivates critical 
enzymes (Wang, et al.;·2003). Activated microglia ean also release cytokines or 
proteases, which may trigger secondary cellular responses on astrocytes or neurons 
(Monnet-Tschudi, et al., 1996), possibly initiating apoptotic mechanisms. 
11.J. On A Cellular Level: Systems Affected by Mercury Exposure 
The various toxic effects of mercury play a role in a number of neurological 
systems, including the glutamate/glutamine cycle, dopaminergic, synaptic transmission, 
GABAergic, glutathione, calcium homeostasis, immune response, and motor activity. 
Sub-micromolar concentrations of HgCli have been shown to inhibit selectively 
glutamate uptake (Faro, et al., 200 I), increasing the concentration of glutamate in the 
synaptic space. Since uptake is the primary inactivation mechanism for synaptically 
released glutamate in the brain, inactivation of glutamate uptake could nevertheless 
accelerate processes of excitotoxic neurodegeneration associated with disease or aging 
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(Brookes .. 1992). Excessive stimulation of the glutamate/glutamine cycle results in a. 
state of excitotoxicity and ends up overwhelming neuroprotective systems, increasing DA 
release .. which in turn increases arachidonic acid production and leads to transferritin 
dysfunction (Weber .. 1999). Activation of ionotropic and metabotropic glutamate 
receptors can trigger the Ca2+ -independent efflux of dopamine (Falkenburger, et al., 
200 I). Even though it is typically an excitatory transmitter, research has suggested that 
glutamate can inhibit dopaminergic pathways in the basal ganglia (Jiao, et al., 2003), 
which would still lead to neurotoxicity because inhibition of the pathways increases the 
amount of excess dopamine in the synaptic space. Although the inhibition of glutamate 
transport can be reversed, this process becomes less reversible when exposed to mercury 
for longer periods of time (Brookes, 1988). Similarly, inhibition of glutamate transport is 
also less reversible with higher concentrations of mercury (Brookes, 1988) due to the 
toxicant's oxidative properties and interaction with membrane proteins. 
Mercury also affects the dopaminergic system. Previous work has shown that 
mercury blocks the degradation pathway of catecholamines (Weinstein and Bernstein, 
2003 ) .. including dopamine. Neuronal dopamine uptake is both sodium- and temperature-
dependent .. indicating an active mechanism for dopamine transport (Hosli and Hosli, 
1 997). The dopamine transporter, located on the presynaptic terminal, terminates 
dopaminergic neurotransmission by accumulation of released dopamine into presynaptic 
neurons ( Dutta, et al., 2001 ). The functional importance of the dopamine transporter lies 
in its ability to clear excess synaptically released dopamine (Wu, et al., 1997). In fact, 
DAT sites represent a major mechanism for the inactivation of DA transmission at the 
synapse .. thus serving a pivotal role in the regulation of DA levels in the central nervous 
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system (Jiao .. et aL. 2003). Dopamine levels can be regulated by drugs that bind to DAT, 
modulating synaptic DA concentrations through different mechanisms (Eshleman, et al., 
1994 ) .. including blocking the transporter, acting as a substrate and increasing DA release 
or competing for the binding site. Excessive dopamine in the synapse is metabolized by 
one of two oxidation mechanisms. The one mechanism consists of monoamine oxidase-
A or -8 (MAO-A, MA0-8) oxidation of dopamine to produce 3,4 dihydroxyphenyl 
acetate (DHPA)., ammonia and hydrogen peroxide (Hodgson and Smart, 2001). 
DA+ 02 + H20 ~ DHPA + NH3 + H202 
Hydrogen peroxide can be further converted to hydroxyl radical, a toxic reactive oxygen 
species, through. the Fenton reaction. The second mechanism for oxidative breakdown of 
dopamine is auto-oxidation, where dopamine reacts with divalent oxygen to produce a 
semiquinone., a hydrogen ion and a superoxide radical, which can react with another 
molecule of dopamine to form a second semiquinone and more hydrogen peroxide 
(Hodgson and Smart, 2001 ). 
DA +02 ~SQ•+ •02-+lt' 
DA+ •02- + lit' ~ SQ•+ H202 
The production of hydrogen peroxide and other reactive oxygen species can be 
especially damaging to membrane integrity, DNA synthesis and overall cellular function. 
Although removing dopamine via reuptake by the DAT can prevent initiation of the 
dopamine metabolism mechanisms, this process can also be enhanced by the stimulation 
of dopamine release or production of reactive oxygen species (Weber, 1999). Excess 
dopamine can bring about dopamine-induced apoptosis in neuronal cells; however .. the 
extent of cell death depends on reuptake of dopamine, intracellular thiol modulation., and 
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mitochondrial function (Zhang, et al., 1998). Alteration and/or disruption of dopamine 
transport leads to dopamine accumulation in the synaptic space, resulting in the 
production of destructive reactive oxygen species via dopamine metabolism. 
Mercury-induced toxicity is known to affect synaptic transmission. Mercury 
interferes with signal transduction pathways due to the fact that this toxicant changes 
tyrosine phosphorylation of proteins and pathways regulated by receptor-associated 
tyrosine kinases, like nerve growth receptors (Mattingly, et al., 2001). The research of 
Wang and colleagues (2003) concluded oxidants such as mercury, are involved in the 
activation of multiple signaling pathways contributing to cytotoxicity, including the 
phosphorylation cascades leading to the activation of mitogen-activated protein kinases 
(MAPK). In addition to evidence of MAPK activation in brains of Alzheimer's patients, 
this enzyme has also been linked to mediation of apoptosis in neuroblastoma cells (Wang, 
et al., 2003 ). The work of Shanker, Hampson and Aschner (2004) tried to correlate 
methylmercury exposure with phospholipase A2 (PLA2) activity, an enzyme that plays a 
key role in the signal transduction pathways of many receptors. Due to its highly 
lipophilic nature, methyl mercury was found to quickly activate cytosolic PLA2 ( cPLA2) 
levels (Shanker, et al., 2004). Activation of cPLA2 not only catalyzes the breakdown of 
membrane lipids, but it also triggers the release of arachidonic acid (AA), whose pro-
inflammatory metabolites can activate voltage dependent and ligand-gated channels as 
well as contribute to ROS generation and impaired mitochondrial energy synthesis 
(Shanker, et aL 2004). The excessive stimulation of this enzyme, cPLA2, has been 
linked to the etiology of metal encephalopathies, stroke, seizures, cerebral ischemia and 
Alzheimer's disease (Shanker, et al., 2004), which potentially links the effects of 
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mercury-induced neurotoxicity to certain pathologies. Mercury triggers neurotoxicity by 
increasing and then suppressing the spontaneous release of neurotransmitters in the 
periphery (Yuan and Atchison, 1994). The effects ofneurotoxic mercurials depend on 
the site and potency of action, which is directly linked to the lipophilicity of the mercury 
compound .. as well as the possible reversibility of that binding action (Yuan and 
Atchison .. 1994 ). Hg2+ has been shown to increase neurotransmitter release by changing 
intracellular calcium concentrations (Hare, et al., 1990). 
Mercury has also been shown to influence GABAergic function. Alterations in 
GABAergic function have been associated with various neurological and psychiatric 
disorders .. such as Huntington's disease, epilepsy, tardive dyskinesia, alcoholism, 
schizophrenia., sleep disorders, Parkinson's disease and mental retardation (Siegel, et al., 
1999). The two categories of GABA receptors, GABAA and GABA8 , are coupled to 
chloride and potassium ion channels, respectively (Siegel, et al., 1999). The research of 
Gopal (2003) established the GABAA receptor as another neuronal target for mercury, 
interrupting GABA signaling pathways and therefore hindering GABA function. 
Activation of the GABAA receptor mediates er influx, depolarizing the cell membrane, 
which then activates Ca2+ influx (Siegel, et al., 1999) and can trigger apoptotic 
mechanisms. 
As a primary protective mechanism against oxidative stress, one can easily predict 
that mercury-induced toxicity affects glutathione (GSH), an essential antioxidant 
neuroprotector mainly localized in glial cells (Lee, et al., 2001 ). Previous research has 
found that incubation with inorganic mercury at higher concentrations leads to lipid 
peroxidation and a reduction in glutathione (Stacey and Kappus, 1982) .. causing a loss in 
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cell viability. Glutathione depletion can be resultant of synthesis inhibition, conjugation 
of GSH to electrophilic xenobiotics or the effects of oxidative stress (Hultberg, et al., 
2001 ). Although exposure to mercury has shown an initial increase in extracellular 
glutathione (Hultberg .. et al. .. 2001), the toxic process ultimately ends in glutathione 
depletion. The initial surge of glutathione may represent a compensatory mechanism to 
protect against further damage from oxidative stress or a reserve mechanism to replenish 
the gl utathione that has complexed mercury ions. In addition to cellular GSH, 
mitochondrial GSH levels are also diminished under oxidative conditions. As defensive 
systems like glutathione deteriorate due to the generation of ROS, normal mitochondrial 
activity becomes especially susceptible to disruptions in the energy production pathways. 
The research of Stohs and Bagchi ( 1995) noted that the addition of mercury to a system 
enhances hydrogen peroxide formation under conditions of impaired respiratory chain 
electron transport. The resulting depletion of glutathione leads to an increase in reactive 
oxygen species~ like superoxide ion, hydrogen peroxide and hydroxyl radical (Stohs and 
Bagchi, 1995). Resultant damage induced by ROS includes: lipid peroxidation, DNA 
fragmentation as well as altered calcium and sulfhydryl homeostasis. 
As previously mentioned, mercury-induced oxidative stress leads to impairment 
of calcium homeostasis. Oxidative stress due to free radical oxygen species increases 
intracellular calcium by bringing calcium into the cell and releasing inner stores of 
calcium (Stohs and Bagchi, 1995), which are commonly found in the mitochondria. An 
increase in Ca2+ concentration can also trigger apoptotic mechanisms (Amoroso, et al., 
2002). Prior research has revealed that Hg2+ inhibits ATP-dependent calcium uptake into 
intracellular stores (Hare, et al., 1990), such as the mitochondria. The toxic actions of 
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mercury interrupts calcium's role in activating proteases, endonucleases and 
phospholipases (Stohs and Bagchi, 1995). The lack of calcium activity allows for the 
generation of more free radicals, initiating an intracellular signal transduction cascade, 
which can result in long-term potentiation (Weber, 1999) and excitotoxicity. 
Due to the interaction between regulatory mechanisms in the CNS and immune 
systems .. it should not be surprising to learn that mercury's neurotoxic effects can elicit 
peripheral immune responses. Down-regulation of DNA synthesis occurs with mercury-
induced toxicity because mercury hinders this process by binding to the sulfhydryl-
containing amino acids of proteins/enzymes associated with DNA replication; less DNA 
production leads to less cell proliferation, weakening the system. Mercury has been 
shown to influence growth control and regulation of apoptotic mechanisms in 
lymphocytes (Mattingly, et al., 2001), cells whose main function is cell-mediated 
immunity. This same research also observed that Hg2+ alters tyrosine phosphorylation, 
interfering with Ras-mediated signal transduction (Mattingly, et al., 2001). Ras, a small 
G protein that controls growth factor and MAP kinase pathways, mediates cell growth 
(Siegel.. et al., 1999); inactivation or dysfunction of this protein can impede essential 
physiological functions. Due to its high affinity, mercury binds to sulfhydryl groups on 
the cell membrane, creating disulfide bridges, which promotes cellular dysfunction 
(McCabe, et al., 1999). This is a proposed mechanism to explain how mercury interrupts 
the normal activation of tyrosine kinase, an enzyme involved in tyrosine phosphorylation. 
Tyrosine phosphorylation plays a fundamental role in the CNS, including the 
development and function of a neuron, survival and differentiation, the extension of 
axons to their targets and synapse formation and function (Siegel, et al., 1999). This 
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phosphorylation process is also important to synaptic transmission; neurotransmitter 
receptors_ voltage-gated ion channels, enzymes and proteins in neurotransmitter release 
are all dependent on tyrosine phosphorylation (Siegel, et al., 1999). The oxidative 
properties and consequential neurological effects of mercury influence essential 
transduction pathways linked to the immune system, therefore allowing physiological 
systems to become more susceptible to other harmful substances. 
As the clinical symptoms suggest, mercury toxicity affects activity in motor 
neurons. Even at low concentrations, Hg2+ potently depolarizes skeletal muscle and 
reduces the effective resistance of the fibers (Yuan and Atchison, 1994). This 
depolarization could be brought on by the disruption of Ca2+ homeostasis that occurs 
when mercury blocks Ca2+ uptake into nerve terminals (Yuan and Atchison, 1994 ), 
resulting in neuronal dysfunction and possible neuronal death. The work of Pamphlett 
and Pang ( 1998) demonstrated that the presence of inorganic mercury within motor 
neurons therefore appears to behave as a slow-acting neurotoxin that shrinks motor 
neurons. This same effect could shrink the axons of sensory neurons (Pamphlett and 
Pang, 1998), which might explain some of the symptoms seen with mercury 
neurotoxicity, such as hearing loss and impaired vision. 
Il.K. Factors of Toxicity and Possible Chelation Therapy 
The neurological effects of mercury-induced toxicity are dose-, concentration-
and time-dependent. Although low concentrations of mercury were more toxic to 
undifferentiated brain cells (Monnet-Tschudi, et al., 1996), higher (near cytotoxic) 
concentrations of organic mercury had more neurospecific effects (Monnet-Tschudi, et 
al., 1996 ). Accumulation of mercury in targeted brain regions is concentration-
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dependent. The work of Monnet-Tschudi, and associates (1996) offers that mercury. 
compounds accumulate in a concentration dependent manner. Mercury-induced 
nephrotoxicity is both concentration-and time-dependent (Rodilla, et al., 1998). The 
toxic effects of dopamine in the striatum are also dependent on the duration of mercury 
exposure (Faro .. et al.., 2001). Perhaps this could be due to mercury's direct interaction 
with dopaminergic neurons, affecting membranes, vesicular release, reuptake system and 
transport of dopamine or due to mercury's effects on central synaptic transmission in 
respect to its potency and reversibility of action (Faro, et al., 2001 ). 
In order to remove mercury from the central and peripheral nervous systems, the 
search for chelators remains an on-going venture. For example, vitamin E and EDT A, 
two commonly used chelators, had no effect on ultimate cell death induced by mercury, 
though they did prolong cell death by protecting against oxidative stress (Stohs and 
BagchL, 1995). The later work of Gass6 and colleagues (2001) support this conclusion, 
also finding that vitamin E did not in fact reduce HgCh cytotoxicity. Perhaps mercury 
elicits its toxic effects by displacing other divalent ions, which may contribute to more 
oxidative stress, depletion of protective resources and the cell finally succumbs to the 
damage. Due to its strong antioxidant and nucleophilic nature (Rao, et al., 2001), vitamin 
C works against mercury-induced genotoxicity by directly binding to mercury ions or 
removing and/or reducing free radicals generated by mercury toxicity. Though the 
chelation of excess free Ca2+ brought on by chemically induced oxidative stress seems 
like a logical treatment, Ca2+-chelation does not halt free-radical-induced cell death 
(Amoroso., et al., 2002). Melatonin has also been suggested as a possible treatment for 
mercury-induced toxicity. And although melatonin may not directly chelate mercury., it 
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has been shown to decrease the effects of mercury-induced oxidative stress (Olivieri, et 
al., 2000), perhaps due to an upregulation in glutathione. Currently DMPS is considered 
an effective therapeutic agent because the mercury levels in urine increased about I 0-fold 
(Godfrey .. et aL 2003). However, there has been no indication that the mercury present 
in the urine is resultant of successful chelation from the brain, which suggests 
administration of this drug is not a comprehensive treatment for mercury-induced 
neurotoxicity. 
11.L. Links to Alzheimer's Disease 
The work of Zheng, et al. (2003) showed that a toxin's influence on the blood 
brain barrier can be linked to neurological disorders, abnormal brain development, 
chemically-induced swelling of the brain or the onset of neurodegenerative disease. 
Previous research has suggested links between mercury-induced neurotoxicity and 
neurodegenerative disease, mainly Alzheimer's disease (AD). In their research, Hock 
and collaborators (1998) found a correlation between high blood mercury levels and 
increased cerebrospinal fluid (CSF) levels of amyloid p-peptide (AP), a characteristic 
closely associated with AD. Although mutations in the amyloid precursor protein, the 
protein responsible for AP production, have been linked to genetic factors, these 
mutations may also be linked to environmental factors (Hock, et al., 1998), such as 
exposure to heavy metals like mercury. An increase in AP levels has been implicated in 
oxidative stress and free radical production (Olivieri, et al., 2000). It has been theorized 
that mercury alters the action of amyloid precursor protein because the toxicant inhibits 
PKC activity, which is responsible for the abnormal cleavage product, AP (Hock, et al., 
I 998) and therefore causes the formation of AP plaques. 
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Oxidative stress induced by Hg++ has also been shown to increase the 
phosphorylation of tau protein in neuroblastoma cells (Olivieri et al., 2000), a constituent 
of neurofibrillary tangles and classic feature of Alzheimer's. Other studies have also 
found increased an10unts of mercury in brains of AD patients (Markesbery, 1 997). 
Mercury-induced toxicity may contribute to the oxidized protein and DNA found in 
conjunction with Alzheimer's disease; so thus, with elevated Fe, Al and Hg levels, and 
the potential of acting synergistically, the microenvironment of the brain in AD is fertile 
for enhancing free radical generation and lipid peroxidation (Markesbery, 1997). Even 
though it has not been isolated as a clinical diagnostic tool for Alzheimer's, the blood 
mercury levels in early onset AD patients was 3-fold higher than those in control groups 
(Hock, et al., 1998). However, current research has not been able to offer any evidence 
of a direct causal effect of mercury in the pathogenesis of AD (Hock, et al., 1998). 
Later research investigated use of Apolipoprotein E (Apo-E) genotyping as a 
biomarker to determine those with an increased risk of developing AD (Godfrey, et al., 
2003). Apo-Eis a crucial element in the mechanisms that dictate amyloid ~ secretion, 
plaque fo1mation and oxidative stress (Weber, 1999). In addition to the E4 allele being 
identified as a risk factor for AD with a 70% successful prediction rate, Alzheimer's 
patients with mercury-associated symptoms had higher amounts of the E4 allele (Godfrey, 
et al., 2003), suggesting a link between mercury toxicity and the genetic factors that 
determine onset of the neurodegenerative disease. This work suggests that individuals 
with a combination of homozygous e4 allele genotype and mercury exposure would have 
an increased risk of early-onset Alzheimer's disease (Godfrey, et al., 2003). Other Apo-E 
al lei es, e2 and e3, contain sulfhydryl groups, which allow for them to bind and chelate 
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mercury. removing the toxicant from the CNS (Godfrey, et al., 2003) and therefore 
preventing the pathway from proceeding to ~-amyloid production. 
11. !vi. 5:,'ummw:v and HJpothesis 
In summary. mercury-induced toxicity has been linked to several cellular 
functions~ including membrane transport, DNA synthesis, mitochondrial efficiency, 
calcium homeostasis and neuroprotective defense systems. Through experimentation 
with lower concentrations of mercury, this research aims to determine at what levels 
toxicity occurs by performing functional, cellular and binding studies. Based on a 
literature value which defines acute neurotoxicity as having blood mercury levels 
exceeding 200 µg/L (Hock, et al., 1998), the loss of cellular function indicated by 
changes in dopamine uptake, lactate dehydrogenase and caspase enzymatic activity as 
well as affinity and density of the transporter is expected to occur at mercury treatments 
greater than 1 µM (Hg MW=200.59). However, since this toxicity threshold specifically 
describes blood mercury levels, which can be measured in the CSF, the concentration of 
toxicant in the blood may not truly reflect the concentration oftoxicant in the synapse. 
Therefore, this project explores the potential functional, cellular and pharmacological 
changes while focused on potential synaptic concentrations of mercury. 
The HYPOTHESIS of this project is: Concentrations of mercuric chloride, at or 
below levels reported as cytotoxic will have effects on the dopaminergic system in SK-N-
SH cells. These changes could have a profound psychological/motor impact in vivo prior 
to cytotoxic effects normally observed with high concentrations of mercury. 
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III. RESEARCH DESIGN AND METHODS 
/JI.A. General A1ethodo/ogies 
//1.A.1. Cell Culture 
SK-N-SH human neuroblastoma cells were obtained from American Type Culture 
Collection (A TCC~ Manassas, VA) and cultured in RPM!' 1640 without L-glutamine 
(Cellgro .. Media Tech Inc., Herndon, VA) supplemented with 10% heat inactivated fetal 
bovine serum (FBS; Hyclone, Logan, UT) and 1 % Penicillin/Streptomycin solution-
I 0,000 I. U ./mL and I 0,000 µg/mL (Cellgro, Media Tech Inc., Herndon, VA) in vented 25 
cm
2 
cell culture flasks (Coming Inc., Coming, NY). Cultures were maintained at 37°C in 
a 5% CO2 humidified atmosphere. The culture medium was changed twice a week, as 
recommended by A TCC, and confluent monolayers were subcultured once a week at a 
1 :3 ratio using 0.25% ~rypsin, 1.0 mM ethylenediaminetetraacetic acid (EDT A) in HBSS 
without calcium and magnesium salts (Atlanta Biologicals, Lawrenceville, GA) at room 
temperature for 15 minutes in a sterile environment. The cells from passages 4 to 14 
were used to perform the characterization, functional and binding studies. 
For subsequent portions of the project, 1 x 106 cells were seeded into 24-well 
plastic cell culture plates (Costar® 3524, Coming, Inc., Coming, NY) and maintained in 
the complete growth medium. After plating, the cells were allowed at least 24 h to 
adhere to the surface of the well before further experiments were performed. 
111.A.2. [3H] Dopamine Uptake 
After the specified incubation time, the growth medium/assay buffer/nonspecific 
drug/HgCl2 treatment was removed from all wells. Then I 00 µL of assay buffer 
( consisting of 25 mM HEPES, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCJi,. 1.2 mM 
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MgSO.i, 300 mM Ascorbic Acid, 1 µM Pargyline and 2 mg/mL D-(+) Glucose) was . 
added to the control and treatment (drug or metal) wells. The [7, 8 3H] Dopamine (DA), 
0.02 M acetic acid: ethanol ( 1: 1) solution (Amersham Biosciences, UK) required for this 
portion of the assay was prepared by making 1.2X concentration solution diluted with the 
assay butler, yielding a final in-well concentration of20 nM. Next, 400 µL of the 20 nM 
[3H] DA solution was added to all wells and the plate was incubated for twenty minutes 
on a plate shaker (Clinical Rotator, Cat. No. 2500, Eberbach Corp., Ann Arbor, MI) at 
room temperature. D0pan1ine uptake was terminated by removing the [3H] DA solution 
and washing the cells with 2 mL of ice-cold 0.9% NaCl. After the NaCl was removed, 
the cells were detached from the plate upon addition of 150 µL Trypsin-EDTA, 
transferred to scintillation vials (Fisher Scientific, Pittsburgh, PA), and 5 mL scintillation 
cocktail was added to each vial (ScintiVerse®, Fisher Scientific, Pittsburgh, PA), which 
was then capped and vortexed. As well as the vials prepared from each individual well, a 
scintillation vial containing 150 µL of20 nM [3H] DA and 5 mL scintillation cocktail 
was included a means of calculating the amount of dopamine available for actual uptake. 
Uptake was determined by liquid scintillation spectrophotometry using a Beck.man 
Coulter LS 1801 (Beckman Coulter Inc., Fullerton, CA). 
Ill.A. 3. C'ytotoxicity and Necrosis: Measuring Lactate Dehydrogenase (LDH) 
These experiments were carried out using a colorimetric LOH enzyme detection 
kit: CytoTox 96 ® Non-Radioactive Cytotoxicity Assay from Promega Corporation 
(Madison, WI). This kit quantitatively measures lactate dehydrogenase through the series 
of enzymatic reactions seen below: 
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LDH 
NAD+ + Lactate ~ Pyruvate + NADH 
Diaphorase 
NADH + INT ~ NAD+ + Fonnazan 
In the first step of this process, NAD+ is reduced to NADH as the LDH released from 
affected cells catalyzes the conversion oflactate to pyruvate. In the second step, an 
electron-accepting catalyst, such as diaphorase, transfers the proton from NADH to the 
tetrazolium salt (INT), which is reduced to fonnazan, a red-colored product. 
The general protocol begins by transferring 50 µL of each sample into a clear 96-
well flat-bottom cell culture plate (Costar® 3599, Coming Inc., Corning, NY) in 
duplicate. Blanks were included as a means of subtracting out any background 
absorbance attributed to assay buffer or media, again using 50 µL aliquots of assay buffer 
(refer to section 111.A.3) or media. The assay buffer·was then thawed, and while 
protected from the light, acclimated to room temperature. A 12-mL portion of the LOH 
assay buffer was used to reconstitute a bottle of substrate mix. Then 50 µL of substrate 
mix solution was then added to each well of the 96~well plate. After the reaction mixture 
was incubated for 30 minutes at room temperature, again protected from light, 50µL of 
stop solution (1 M acetic acid) is added to each well. Within an hour of when the 
reaction was stopped, the absorbance was measured at 490 nm with the Synergy TM HT 
Multi-Detection Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT.), which 
uses KC4™ PC Software to report absorbance data. 
111.A.4. Initiation of Apoptotic Mechanisms: Detection of Caspase-3 and-7 
These experiments were done using a caspase enzyme apoptosis kit: Apo-ONE 
TM 
Homogeneous Caspase-3/7 Assay, from Promega Corporation (Madison, WI). Toxin-
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induced apoptosis activates different caspases, which are responsible for triggering a . 
cascade of cleavage events that result in the methodical destruction of cells. The caspase 
3/7 substrate. consisting of rhodaminel 10, bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-L-
aspartic acid amine) (Z-DEVD-Rl 10) allows for the fluorescent detection of caspase 3/7 
activity. The amount of caspase 3/7 activity can be measured because as the caspase 3/7 
enzymes present in the sample initiate the cleavage and removal ofDEVD peptides (Asp-
G I u-Val-Asp ). an intensely fluorescent product (the rhodamine 110 leaving group) is 
created. which has an excitation wavelength of 499 nm and a maximum emission 
wavelength of 521 nm. Therefore, the total amount of fluorescence measured is 
proportional to the amount of caspase 3/7 contained in the cells from each sample. 
First, I 00 µL from each individual sample was put into a black 96-well clear-
bottom cell culture plate (Costar® 3603, Corning Inc., Corning NY) in duplicate. 
Blanks were included (also performed in duplicate) with each assay to account for any 
background fluorescence contributed by the various solutions used during toxin 
incubation, such as the growth medium or uptake buffer, again using 100 µL aliquots. 
While protected from the light, the Apo-ONETM Homogeneous Caspase-3/7 Buffer and 
Caspase Substrate Z-DEVD-Rl IO were thawed to room temperature. The Caspase 
Substrate was diluted I: I 00 with the Caspase-3/7 buffer to the desired volume and mixed 
by inversion. Then I 00 µL of the caspase reagent was then added to each well of the 
plate and incubated on a plate shaker for the desired amount of time, anywhere from 30 
minutes to 18 hours depending on the expected amount of caspase activity at room 
temperature. again protected from light. Within 18 hours of the post-incubation time, the 
fluorescence was measured at 499 nm (excitation wavelength) and 521 nm (emission 
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wavelength) with the Synergy™ HT Multi-Detection Microplate Reader (Bio-Tek 
Instruments. Inc"' Winooski, VT.), which uses KC4 ™ PC Software to report absorbance 
data. 
111.A.5. Binding Studies: Affinity and Density of the Dopamine Transporter 
After treatment with mercury, the cells were trypsinized, centrifuged to form a 
pellet and frozen to later perform saturation analysis. 
Cell pellets were resuspended in assay buffer to yield a final protein concentration 
of 0.003 - 0.03 mg/mL .. using assay buffer. Assay buffer consists of 50 mM Tris-HCI, 
120 mM NaCl and 0.01% bovine serum albumin adjusted to pH of7.7. After 
resuspension~ 400 µL of the cell preparation is added to 12 x 75mm polypropylene 
binding tubes followed by 50 µL of either buffer (control) or unlabeled drug. The 
binding reaction is initiated by the addition of 50 µL of increasing concentrations of [3H] 
GBR-12935 (6 concentrations, 1 nM - 30 nM) both in the absence and presence of 5 µM 
GBR-12909 and allowed to proceed at room temperature for 60 minutes. Binding is 
terminated by filtration under reduced pressure using a Brandel Tissue Harvester 
(Brandel Instruments, Gaithersburg, MD) onto GF/B fiberglass filters which had been 
presoaked in 0.3% polyethyleneimine to reduce nonspecific binding. Filters are then 
washed for 15 seconds (approximately 15 mL) with ice-cold 50 mM Tris-HCl (pH 7.4). 
Specific [3H] GBR-12935 binding is then determined by the subtraction of binding in the 
presence of 5 µM GBR-12909 from binding in the absence of any drugs (total binding). 
These data will allow for the determination of the density and affinity of the dopamine 
transporter. [3H] GBR-12935 binding to the dopamine transporter is then determined by 
liquid scintillation spectrophotometry. 
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Ill. B. Data Ana(vsis and Statistics 
The data from the previously described experiments was recorded as % Control [3H] 
Dopamine Uptake, Absorbance at 490 nm, Relative Fluorescence Units (RFU), Affinity 
of [3H] GBR-12935 for DAT (nM) and Density (pmol/ mg protein) of DAT. Appropriate 
statistical analyses were performed using GraphPad Prism® Version 4.0 (San Diego, 
CA). Parametric analysis using one- and two-way analysis of variance (ANOV A) was 
accepted since the data met both the concept of normal distribution and robustness. Post-
hoc analysis was performed using the Bonferroni correction for multiple comparisons or 
Dunnett's Multiple Comparison Test that compares treatment values to control values. A 
value of P < 0.05 was used to indicate significant differences. 
II I. C. Experimental Design 
111.C. 1. Cell Culture 
The SK-N-SH cultures were prepared as described above and all procedures were 
performed while utilizing 'sterile' techniques. 
Maintenance of cells included changing the complete growth medium twice a 
week and splitting the cultures once a week. To change the media, the old media was 
taken out using a sterile pipette; careful not to disturb the monolayer of cells. 5 mL of 
warmed complete media (heated in 37°C water bath for 20-30 minutes) was added to the 
flasks without creating bubbles. 
Upon achieving confluence, within 7 days, the cells were split and subcultured in 
a 1 :3 ratio. Using a pipette, the medium was removed and 1.5 mL of trypsin (thawed in 
37°C water bath) was added to each 25 cm2 flask. Typically, cells will loosen from the 
culture surface in 5-15 minutes; the flasks can also be returned to the incubator if the cells 
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begin to clump or do not appear to be detaching from the plastic; gentle agitation can.be 
used as a last resort. Once the cells are removed from the surface, 3.5 mL of complete 
media was added to each flask to stop the action of the trypsin. Pipetting the solution up 
and down breaks up any clumps and disperses the cells in the suspension. Depending on 
the confluence of the monolayers, 0.5-1.0 mL of the cell suspension was transferred to a 
new sterile 25 cm2 culture flask and 4.5-4.0 mL of complete media was added to each 
new flask .. again avoiding bubbles, maintaining a 5 mL final volume. After the splitting 
procedures were completed, all culture flasks are recapped and returned to the incubator. 
11/.C.2. Characterization of the Dopamine Transporter Using GBR-12909 and Mazindol 
In order to determine a drug's affinity for the dopamine transporter, competition 
binding assays are performed to measure the competition between a radioligand and an 
unlabeled drug for a specific receptor site (Hodgson and Smart, 2001). The cells were 
treated with a range of drug concentrations and incubated with [3H] DA to measure 
changes in dopamine uptake. The uptake inhibitory drugs examined include: Mazindol, 
Desipramine, GBR-12909 and Nomifensine. 
The cells were plated as described above. The drugs (Mazindol and GBR-12909 
from RBI. Inc ... Natick MA) were prepared by making 5X concentrations diluted with the 
assay buffer .. accounting for the I :5 dilutions into each well (IOOµL drug in a total 
volume of 500µL/well). The growth medium was removed, I 00 µL assay buffer was 
added to control wells ( defining total uptake) and I OOµL of drug concentrations ranging 
from 0.1-1000 nM were added to the treatment wells. After administration of drug, the 
dopamine uptake procedures explained earlier were carried out to quantify the amount of 
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dopamine uptake blocked by the various inhibitors, which correlates to the drug's affinity 
for the dopamine transporter. 
The uptake data was reported as Mean% Control Total [3H] Dopamine Uptake± 
SEM of four experiments performed in duplicate and evaluated using one-site 
competition analysis. The inhibitory constant (Ki), defined as the concentration of drug 
that will inhibit 50% of the observed response taking into account the affinity of the drug 
for its site of action with respect to the affinity of the substrate for its receptor, was 
calculated for the different tested using the equation: 
Ki= EC~ 
I + [ligand]~ 
The effective concentration 50% (EC50) value reflects the ability of the drug to bind to its 
receptor (affinity) and the ability of the drug to cause a response once it is bound 
(efficacy)~ essentially the concentration of drug that competes for half the specific 
binding. For these calculations, the EC50 value for the individual drugs was supplied by 
the analysis from one-site competition, the Kd of [3H] Dopamine for DAT was found to 
be 70 nM and I 00 nM was used for the concentration of ligand to best approximate the 
concentration of [3H] Dopamine having the affinity Ki. 
The term fractional occupancy is used to describe receptor occupancy as a 
function of ligand concentration; for these assays, the amount of dopamine transported 
(uptake) as a function of drug concentration. The formula for fractional occupancy is 
shown below: 
Fractional Occupancy= [Ligand/Drug] 
[Ligand/Drug] + Kd 
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Kd .. the dissociation constant, defines the affinity of the ligand for the binding site of . 
interest~ in this case .. the affinity of the uptake inhibitor for the dopamine transporter. 
Based on the data collected for the different inhibitory drugs, appropriate DA uptake 
inhibitors were chosen to use later in the uptake assays after mercury exposure. 
As prior research indicated, GBR-12909 was shown to have a higher affinity 
{approximately 150-fold) for the DAT compared to NET. Mazindol has been reported to 
have a slightly higher affinity for NET (7-fold) compared to DAT. Thus, suggesting that 
GBR-12909 is a selective uptake inhibitor for the dopamine transporter (DAT) over the 
norepinephrine transporter (NET). Use of appropriate concentrations of both drugs could 
facilitate the determination of DAT and NET density. By incubating with low 
concentrations of GBR-12909 (50 nM/DAT) and high concentrations ofmazindol (1 
µM/DAT+NET), one can mathematically calculate the density of DAT and NET using a 
single radioligand. 
Jll.C.3. HgC/2 Treatments 
SK-N-SH cells were plated as described above and exposed to varying 
concentrations of Mercury (II) Chloride (HgCh; Sigma Aldrich, St. Louis, MO) over 
different periods of time. Incubation with HgCh was carried out in assay buffer, 
complete media and modified assay buffer (without ascorbic acid). 
For the experiments performed in the buffer, the inorganic salt was accurately 
dissolved in Milli-Q water to make a I mM stock solution; then aliquots of the original 
stock solution were diluted with the assay buffer up to the final HgCb concentration used 
for the various treatments. Throughout the course of experimentation, two stock 
solutions were made for the mercury treatments done in the buffer because over time .. the 
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mercury in the first solution had begun to visibly precipitate out of solution. The first 
stock solution ( I mM) was prepared by dissolving 3.30 mg ofHgC12 into 12.15 mL of 
Milli-Q water .. while the second stock solution (lmM) was prepared by dissolving 3.50 
mg of HgCb into 12.89 mL of Milli-Q water. The mercury treatments were prepared, 
being mindful of the I :5 dilution factor (I OOµL of treatment in 500µL total). The growth 
medium was removed and 400 µL of assay buffer was added to each well. Then 100 µL 
of the different HgCb concentrations, ranging from 1 nM to I mM, were added to each of 
the treatment wells and incubated at room temperature for the specified exposure time, 
beginning with I h and extending to 6h. 
For the experiments performed in the growth medium, the inorganic salt was 
accurately dissolved in Milli-Q water to make a 51 mM stock solution. This stock 
solution was prepared by dissolving 13.85 mg ofHgCh into 100.54 mL of Milli-Q water 
and then autoclaved to sterilize the solution. Then aliquots of the sterile stock solution 
were diluted with sterile water up to the final HgC}i concentrations, varying from 1 OµM 
to I mM to be used for the different treatments. Preparation of these mercury treatments 
required a different dilution factor of I :51 because IOµL of treatment was added to the 
SOOµL of media already in the wells, creating a total volume of 51 OµL. The rationale for 
using a lower volume was to minimize the dilution of media constituents. IO µL of the 
various sterile HgCb concentrations were added directly to the complete growth medium 
in each of the treatment wells and maintained in a 37°C, 5% CO2 humidified atmosphere 
for the specified exposure time, ranging from lh to 48h. 
Later experiments investigated the potential effects of specific components in the 
original assay buffer~ namely ascorbic acid. These treatments were performed the same 
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as the other 'in buffer' studies, except that the aforementioned 300 mM ascorbic acid was 
not added to the assay buffer used in this.part of the experiment. This 'modified' buffer 
was utilized to make the mercury treatments and was put in the wells during the exposure 
period. This limited study focused on moderate concentrations, ranging from 1 µM to 
I 00 µM and an exposure time of 6h. 
Ill. C. 4. Measuring [3 HJ Dopamine Uptake After Toxin (Hg2+) Exposure 
This procedure was performed in accordance to the aforementioned protocol with 
a few modifications. Once the exposure period expired and the solution 
(media/buffer/mercury) was removed from all wells, I 00 µL of 250 nM GBR-12909 and 
I 00 µL of 5 µM. mazindol (diluted with assay buffer (refer to section 111.A.3)) were added 
to designated wells (with resultant 'in well' concentrations of 50 nM GBR-12909 and 1 
µM mazindol) while I 00 µL of assay buffer (refer to section 111.A.3) was put into control 
and mercury-treated wells. Nonspecific binding was defined as [3H] DA uptake in the 
presence of 50 nM GBR-12909 and uptake in the presence of I µM mazindol. All other 
steps in the process were carried out as previously ·described. 
Data were reported as Mean % Control [3H] Dopamine Uptake ± SEM of four 
experiments done in duplicate. Data were analyzed by either two-way ANOV A (time by 
concentration) or one-way ANOV A ( concentration) to determine effects on [3H] 
dopamine uptake. 
Ill. C. 5. Cytotoxicity and Cell Viability: Measuring Lactate Dehydrogenase (LDH) 
The concentration(s) and exposure time period(s) were chosen in conjunction with 
the changes noted in the dopamine uptake data. Based on the uptake studies, the cells 
were exposed to 5 µMand 50 µM HgC12 for 24 hours in both media and assay buffer 
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(refer to section 111.A.3). Because of the 1 :10 dilution (a 50 µL mercury treatment in 500 
µl total volume)_ 50 µMand 500 µM solutions were prepared; dissolving 7.1 mg of 
HgCl2 in 52.30 ml of Milli-Q water for the 500 µM solution and dissolving 1.2 mg 
HgCl2 in 88.40 ml of Milli-Q water for the 50 µM solution. To maintain a sterile 
environment during the 24h incubation period, the two mercury treatments were 
autoclaved_ as well as a portion of assay buffer. 
To begin this procedure., SK-N-SH cells were plated out in a 24-well plate as 
previously described. After allowing time for the cells to adhere to the culture surface, 
the growth medium was removed and 450 µL of incubation solution (complete media or 
assay buffer) was added to the respective wells. Then, 50 µL of the 5 µMand 50 µM 
HgCb treatments was added to the proper wells and the plate was returned to the 
incubator (3 7°C) for 24h. 
Once the 24h treatment period had finished, the procedures for measuring LDH 
commenced. The aforementioned protocol was followed with minimal modifications. In 
order to account for background absorbance contributed by both incubation solutions, 
duplicate 50 µl aliquots of complete media and assay buffer served as blanks for the 
experiment. 
Data were reported as Mean Absorbance at 490 nm± SEM of four experimental 
samples run in duplicate. Data were analyzed by one-way ANOV A (absorbance at 
490 nm) to determine any differences between the various groups: control, 5 µM 
treatment and 50 µM treatment. 
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1//.C.6. Initiation ofApoptotic Mechanisms: Caspase-3 and-7 Detection 
Immediately following procedures for the LDH experiment, preparations for 
measuring caspase activity began. From the same 24-well plate, all remaining solution 
was removed and 150 µL of trypsin was added to each well. After the cells had loosened 
from the culture surface, 50 µL aliquots of trypsinized cefls from each of the 24 sample 
wells were transferred in duplicate to a black 96-well plate. In order to maintain the cells 
during incubation period for the caspase assay, 50 µL of complete media was added to 
each of the wells on the 96-well plate, resulting in a total volume of I 00 µL per well, 
diluting the cells by a 1: 1 ratio (50 µL of cells in I 00 µL total). The 96-well black plate 
was allowed to sit for approximately 2h so that the trypsinized cells from each sample 
could re-adhere to the culture surface. 
In order to account for any background fluorescence contributed by the 
combination of incubation solutions, blanks consisting of 50 µL trypsin and 50 µL 
complete media were also performed in duplicate. As indicated in the general protocol, 
the 1 OOX caspase reagent solution required for the assay was prepared by mixing I 00 µL 
of Z-DEVD-Rl IO caspase substrate with 9.9 mL of caspase buffer. The aforementioned 
procedures concerning the Caspase-3/7 Assay were followed, incubating the covered 96-
well black plate for 6h at room temperature, mixing the contents for the first 30 minutes 
on a plate shaker. 
By using KC4 TM PC Software to measure fluorescence, the parameters for the 
excitation and emission wavelengths were slightly modified. Excitation wavelength was 
set at 485 ± 20 nm and emission wavelength was set at 528 ± 20 nm; both of these ranges 
contain the original wavelengths recommended by the general protocol. The data were 
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reported as Mean Relative Fluorescent Units (RFU)± SEM of four experimental samples 
run in duplicate. Data were analyzed by one-way ANOVA (RFU) to establish if there are 
changes in relative fluorescence between groups: control, 5 µM treatment and 50 µM 
treatment. 
Ill. C. 7. Binding Studies: Affinity and Density of the Dopamine Transporter 
For these experiments cells were subcultured in 25 cm2 flasks and flasks were 
randomly subdivided into 3 groups; control/vehicle, 5 µM HgCh, and 50 µM HgCb. 
Cells were allowed to adhere for at least 24 hours and then treated by the addition of the 
appropriate solution. Control groups received 500 µL of sterile double distilled water 
( ddH20)~ whereas the mercury groups received either (final concentration) 500 µL of 5 or 
50 µM HgCl2. The flasks were then returned to the incubator (37°C) and allowed to sit 
for 24h. The reaction was terminated by the removal of growth media with ddH20 or 
mercuric chloride and addition of 1.5 mL of 0.25% trypsin/0.03% EDTA. Following 
trypsinization, cells were centrifuged to form a pellet and the pellet frozen until assayed. 
The saturation analysis was performed as described above. The data were 
analyzed by fitting a rectangular hyperbola to determine Kd (affinity) and Bmax (density) 
values. 
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IV. RESULTS 
IVA. ( 'haracterization of the Dopamine Transporter Using GBR-12909 and Mazindol 
Analysis of the data revealed the different affinities each drug had for the 
dopamine transporter. Figure 4 shows competition analy~is curves that were used to 
evaluate the inhibitory constants (Ki values) for mazindol and desipramine. 
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Figure 4. Effects of Mazindol and Desipramine on [31-1] Dopamine Uptake in SK-N-SH cells. 
Uptake in the presence of 0. I nM - I OµM of inhibitol)' drug is expressed as Mean% Control 
[ 3H] Dopamine Uptake± SEM of 4 experiments, each run in duplicate. By using One-Site 
Competition Nonlinear Regression Analysis, the Inhibitol)' Constant (Ki) values for the two 
drugs of interest were calculated. 
Ki values were used to determine which drugs were more selective for DAT. According 
to Hodgson and Smart (2001 ), Ki is the equilibrium dissociation constant of the unlabeled 
competitor mazindol, desipramine, GBR-12909 and cocaine, while Kd is the dissociation 
constant of the radio ligand the [3H] Dopamine. Ki values of different toxicants or drugs 
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can be compared to determine the rank order of potency oftoxicants in competing for the 
radiolabeled receptor site, where a low Ki indicates a high affinity and a higher Ki 
indicates a lower affinity. The data in Table 1 summarizes the inhibitory constants 
obtained from the competition analysis yielding a potency series for the four drugs 
examined. 
Table 1. Dissociation Constants for DAT ligands calculated using One-Site 
Competition Nonlinear Regression Analysis 
Ligand N Ki+SEM(nM) 
Mazindol 4 1.52 ± .52 
Desipramine 4 6.91 ± 6.2 
GBR-12909 3 21.6 + 5.8 
Cocaine 3 56.6 + 20.5 
As the data indicate, GBR-12909 was shown to have a high affinity for the dopamine 
transporter, suggesting that GBR-12909 is a potent uptake inhibitor for the dopamine 
transporter (DAT). Interestingly, all curves were best fit to a single, non-interacting, site. 
One would have expected that if there were two sites (DAT and NET) on the SK-N-SH 
cells, two sites would be observed based on the drugs' inherent selectivity. Or, if there 
were only one site~ for example DAT, that GBR-12909 would exhibit a high affinity and 
desipramine a low affinity. Additional work is needed to further elucidate the exact type 
of transport system that is present on SK-N-SH cells. One hypothesis is that in 
undifferentiated cells, a "generalized" transport system is expressed with high affinity for 
both DAT and NET uptake inhibitors and that following differentiation; more distinct 
DAT and NET transport sites would be observed. 
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Based on Table 2. which summarizes the approximate affinities for various clr.ugs 
based on literature values. the fractional occupancy of GBR-12909 and mazindol was 
calculated ( Table 3) with respect to the different transporters. 
Table 2. Approximate reported affinities of different drugs for the dopamine 
(DAT), norepinephrine (NET) and serotonin (SERT) transporters 
Drug DAT Affinity NET Affinity SERT Affinity 
GBR 12909 lnM I50nM >I µM 
GBR 12935 6nM 220nM >5µM 
Indatraline 6nM 2nM 0.5 nM 
Mazindol 15 nM 1-2nM IOOnM 
Nomifensine 98nM lOnM 840nM 
Nisoxetine >l µM 5nM >I µM 
Desipramine >5 µM 4nM 60nM 
Fluoxetine >5 µM >5µM 3nM 
Table 3. Fractional Occupancy of the two DAT ligands utilized to define 
nonspecific binding in measuring [3H] Dopamine Uptake for SK-N-SH cells. 
Transporter GBR-12909 Mazindol 
(% Receptor Occupied) (% Receptor Occupied) 
DAT 98.04 98.5 
NET 25.0 99.9 
SERT 4.76 90.9 
GBR-12909 occupied a greater percentage of receptors on dopamine transporters when 
compared to norepinephrine and serotonin. The percentages of occupied transporter 
receptors for mazindol were approximately the same whether they were dopamine, 
norepinephrine or serotonin transporters. These data support that GBR-12909 is more 
selective for the dopamine transporter, while the nonselective nature of mazindol is 
confirmed by the comparable percentages of occupied receptors for the different 
transporter proteins. 
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IV. B. Afeasuring [3 HJ Dopamine Uptake After Mercury Exposure 
For the experiments where the incubation period was carried out in assay buffer at 
room temperature prior to performing the dopamine uptake procedures, lower 
concentrations ( I nM-1 µM) of mercury elicited little to no change in dopamine uptake 
when compared to control values. as seen in Table 4. A similar trend was seen at similar 
concentrations over more moderate periods of time (6h). 
Table 4. Dopamine Uptake Values in Assay buffer (refer to section 111.A.3). 
Data expressed as Mean % Control [3H] Dopamine Uptake± SEM of 4 
experi1nents done in duplicate. ND= Not Determined. Control values 
defined as 16.0 ± 1.2 fmol/min of dopamine being taken up for these sets of 
experiments. · 
/HgC/2/ 1 Hour 3Hour 6Hour 
InM 79.4 ± 6.1 90.6 ± 7.6 ND 
10 nM 83.0 ± 3.8 93.8 ± 6.7 ND 
100 nM 83.7 ± 3.9 103.9 ± 7.5 87.6 ± 10.8 
lµM 98.1 ± 12.4 85.2 ± 7.6 82.6 ± 8.2 
10 µM 106.3 ± 7.5 90.3 ± 5.8 72.5 ± 7.8 
100 µM 112.8 ± 8.8 93.5 ± 3.6 54.4 ± 17.9 
Although there was no significant effect of concentration (F 5,54=0.20; p = 0. 9619) 
on dopamine uptake~ the data does indicate a significant concentration X time interaction 
(F 10,s4=2.49; p = 0.0154) and a significant (F2,s4=6.35; p = 0.0033) effect of time. There 
was also a significant (F s,36=2. 79; p = 0.0315) concentration X time interaction with 
comparing 1 h and 3h data sets (Figure 5). 
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Figure 5. Effects of mercuric chloride on [3H] Dopamine Uptake in SK-N-SH cells 
for 1- and 3-hour exposure periods. Uptake in the presence of lnM - 100 µM HgCl2 
was expressed as Mean% Control [3H] Dopamine Uptake± SEM of four 
experiments., each run in duplicate. These mercwy treatments were performed in 
assay buffer. The data indicate a significant interaction between both concentration 
and time in mercury-exposed cells at shorter time points and smaller concentrations 
when compared to control values. Control values defined as 18.6 ± 1.3 finol/minute 
of dopamine being taken up for these sets of experiments. 
At moderate concentrations of mercury ( 1 OOnM-1 OOµM), significant time-
dependent effects (F 1.36 = 7.91; p = 0.0079) were observed between 1- and 6-hour 
exposure periods performed in the assay buffer (refer to section III.A.3). The data in 
Figure 6 demonstrate that as the incubation time for exposing the SK-N-SH cells to the 
same concentrations of mercury increases, there is more of a defined decrease in 
dopamine uptake. 
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Fik,TUre 6. Eftect of mercuric chloride on [3H] Dopamine Uptake in neuroblastoma 
ce I ls for I h and 6h ~xposure periods. Uptake in 'the presence of 1 OOnM - I OOµM 
HgCI2 was expressed as Mean% Control [3H] Dopamine Uptake± SEM of four 
experiments, each run in duplicate. Mercwy treatments were perfonned in the DAT 
assay buffer. A significant effect of time was observed (p<0.01) as the exposure 
time increases, dopamine uptake decreases. Control values defined as 15.1 ± 1.6 
finol/minute of dopamine being taken up for th~se sets of experiments. 
A significant effect of concentration (F3,32 = 43.93; p < 0.0001) in dopamine 
uptake was seen when the neuroblastoma cells were treated with mercury for longer 
periods of time (24h) in the complete RPMl-1640 at 37°C compared to DA uptake buffer 
(Figure 7). During the actual experimentation, after treatment with higher concentrations 
of HgCl2 (> IO µM) it was observed that the cells were no longer attached to the culture 
surface; appearing much like the cells had been trypsinized. The data typifies a biphasic 
response pattern; where incubation with moderate concentrations of mercury reflects 
control values and as the concentration of toxin increases, there is a distinct upsurge in 
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dopamine uptake on the order of 3 times control values followed by a severe reduction in 
dopamine uptake. 
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Figure 7. Effects of mercuric chloride on [3H] Dopamine Uptake in SK-N-SH 
cells after 24-hour exposure treatments. Uptake in the presence of 100 nM - I 
mM HgCl2 was expressed as Mean% Control [3H] Dopamine Uptake ± SEM of 
four experiments, each run in duplicate in complete RPtvfl-1640. A significant 
effect of concentration (p < 0.0001) was observed. Control uptake was 10.3 ± 
1 . 8 fmo I/minute of dopamine being taken up for these sets of experiments. 
A similar phenomenon was noted in the uptake studies performed using greater 
concentrations of mercury over a range of time points, again treating the SK-N-SH cells 
with mercury in the growth medium at 37°C (See Figure 8). In addition to the 
experiments run for 24-hours, cells were also visibly floating in the growth media after l-
and 6-hour exposure periods to concentrations greater than IO µM HgCh. The data 
reveal that dopamine uptake increased by 2.5- to 3-fold at all monitored time points (I, 6, 
24 h) when treated with lesser concentrations (I OµM) of mercury. Incubation with 
higher concentrations of mercury ( I OOµM-500µM) resulted in extreme inhibition of 
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dopamine up take. again at all monitored time points (I, 6, 24 h). Statistical analyses of 
the data reveal a significant effect of con~entration (F3.36 = 298.2; p < 0.0001) in 
dopamine upta ke. Bonlcrroni posttests were employed to compare the uptake measured 
wi th each indi\'idual concentration to the other concentrations. As the data illustrate, 
these analyses revealed a significant difference (p < O.OOi) between dopamine uptake 
measured after l O FM HgC!i treatment and the dopamine uptake measured after 100, 
250. and 500 ~1M I IgCI:! treatments at all time points (1, 6, 24h). No significant effect of 
time (F:u<i = 1.04: p = 0.3641) in dopamine uptake between 100, 250 and 500 µM HgCh 
treatments. It is also important to point out that the amount of dopan1ine uptake did not 
appear to vary over the range of time points at any one individual concentration. 
(lJ 300 10 µM HgCl2 100 100 µM HgCl2 ~ 
e,: 
- 75 Q. 
;::) 200 
(lJ 50 
C 
s 100 25 
e,: 
Q. 
0 0 0 Q 6 24 6 24 
-
100 100 
:c: 
250 µM HgCI2 ~ 500 µM HgCl2 75 75 
-0 
i.. 
-
so 50 C 
0 
u 25 25 
~ NO 0 0 0 
6 24 48 6 24 
Figure 8. Effect of various exposure times and multiple concentrations of 
mercuric chloride on [3H] Dopamine Uptake in SK-N-SH cells. Uptake in the 
presence of I 0-500 µM HgC l2 is expressed as Mean% Control (3H) Dopamine 
Uptake± SEM of four experiments, each run in duplicate. Control values defined 
as 8.0 ± 1.3 finol/minute of dopamine being taken up for these sets of 
experiments. All treatments were perfonned in the growth medium. The data 
reveal a significant effect of concentration between the dopamine uptake 
meas ured after exposure to IO µM HgCI2 and all other concentrations (P < 0.00 I. 
two-way ANOV A. Bonferroni Multiple Comparison Test). 
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As reported earlier. there was minimal difference noted in the dopamine uptake 
compared to control values during the experiments run in assay buffer (refer to section 
111.A.3) ,vhen the neuroblastoma cells were exposed to mercury for 6 h. However, when 
the same experiments were carried out in assay buffer (refer to section 111.A.3) containing 
no ascorbic acid (Vitamin C). there was a substantial decrease in dopamine uptake upon 
exposure to 10 ~tM HgCb. which was not indicated by the previous data. Alterations in 
assay buffer (with or without ascorbate) resulted in significant effects of buffer 
composition (F 1.30 = 14.60; p = 0.0006), concentration (F2,3o = 11.04; p = 0.0003) and a 
significant interaction (F2.30 = 4.369; p = 0.0216) between the two parameters (Figure 9). 
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Figure 9. Effects of mercuric chloride on [3H] Dopamine Uptake for 6 hour 
treatment~ comparing dopamine uptake when the neuroblastoma cells were 
treated in assay buffer or ascorbate- free assay buffer. Uptake in the presence of 
0. 1-200 µM HgCl2 is expressed as Mean% Control [3H] Dopamine Uptake ± 
SEM of four experiments, each run in duplicate. Control values defined as 12.4 ± 
1.3 fmol/minute of dopamine being taken up for these sets of experiments. The 
data shows a significant effect of buffer composition during the 6 h treatment 
period (P < 0.001, two-way ANOV A). 
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The differences in the control values of dopamine taken up (finol/min) are a result 
of several contributing factors, such as what passage the cells were in when the assays 
were performed. how many cells were seeded into the wells, and how much time had 
passed between initial plating and actual experimentation. To standardize these variables 
and normalize the raw information gathered, data were expressed as Mean %Control [3H] 
Dopamine Uptake. 
IV. C. ( )·totoxicity and Cell Viability 
The amount of absorbance measured using the CytoTox 96® Assay relates to the 
quantity of LOH released from the cells in that the colored product is resultant of 
catalysis in the presence of LDH. Absorbance of each sample is obtained by subtracting 
out the average value for the appropriate blank. 
Analysis of the absorbance data using one-way ANOV A revealed a significant 
( F 2.11 = 14. I 8; p = O.0017) difference between groups when treated with these 
intem1ediary concentrations of mercury. Since there is a difference seen in the results of 
ANOVA, post-hoc analysis was employed to identify changes in overall main effects. To 
determine which group means differ and to what extent, Dunnett's Multiple Comparison 
Test., a conservative statistical test which compares treatment groups to control values, 
was used. According to the analysis, a significant difference in cytotoxicity was noted 
between the 50 µM HgCb treatments and control values (p < 0.01), while no significant 
difference was detected between the 5 µM HgCli treatments and control values (P > 
0.05). As seen in Figure 10, there is a distinct increase in absorbance when the cells are 
exposed to mercury, especially the larger concentration; this signifies an increase in LOH 
release upon treatment with mercury. 
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Fih11.1rc I 0. EiTects of mercuric chloride on LOH release in SK-N-SH cells for 24h exposure 
period carried out in complete media. LDH release in the presence of 5 and 50 µM HgCl2 
is designated as Mean Absorbance at 490 nm± SEM of four samples run in duplicate. 
There was a significant difference between the 50 µM HgCJ2 and control values (P < 0.01. 
Dunnett's Multiple Comparison Test), yet no difference was observed between 5 µM HgCl2 
and control values. 
!VD. Initiation <?/Apoplotic lvfechanisms: Caspase-3 and-7 Detection 
. TM 
The amount of fluorescence measured using the Apo-ONE Homogeneous 
Caspase 3/7 Assay is relative to the quantity of caspase 3/7 enzymatic activity contained 
within the control and treated cells. The Relative Fluorescence Units (RFU) of each 
sample is determined by subtracting out the average value for the trypsin/media blank. 
Statistical analysis of the fluorescence data using one-way ANOV A exhibited an 
overall significant (F2•11 = 4.794; p = 0.0383) difference between groups when treated 
with 5 ~tM mercury concentrations. Similar to the procedures used to evaluate the LDH 
data. Dunnett"s Multiple Comparison Test was the post-hoc analysis employed to discern 
differences between treatment groups and control as well as the magnitude of said 
61 
di fl'crcnces. The data showed the resultant significant difference to be between the . 
fluorescence measured alter the 5~tM HgCh treatments and control values (P < 0.05) and 
not between the fluorescence measured after the 50 µM HgCh treatments and control 
val ucs ( P > 0.05 ). ·rhc data depicts a decrease in RFUs when the cells are exposed to 5 
~LM l lgCI.::! treatments. which represents a decrease in caspase 3/7 enzymatic activity (See 
Figure I I). However. the amount of relative fluorescence then increases back to control 
values when the cells are treated with 50 ~LM HgC12, indicating there is no change in 
caspase 3/7 enzymatic activity for the larger concentration. 
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Figure I I . Effects of mercuric chloride on Caspase 3/7 enzymatic activity in SK-N-SH 
cells during 24h incubation period perfonned in growth medium. Caspase 3/7 enzymatic 
activity is expressed as Mean RFU± SEM of four samples run in duplicate. The data 
indicate a significant difference between the absorbance measured in the 5 µM HgCl2 
treatments and control values (P < 0.05). 
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IV.£. Binding Studies: /{[finity and Density of the Dopamine Transporter 
All curves were fit to a single site with a range of~ values of 6.5 to 27.4 nM 
(Table 5). Affinity for DAT is represented by Kd values, where a higher Kd corresponds 
to a lower affinity and a lower Kd indicates a higher affi~ty. 
Table 5: Smntnary of Kd Values for [3H] GBR-12935 Binding to DAT After 
Mercuric Chloride Treatment (24h) 
Control 5 50 
6.574 
Interestingly~ control Kd values resembled previous report for [3H] GBR12935 binding to 
DAT (6.5 nM). There was a four-fold shift in affinity of [3H] GBR12935 in the 5 µM 
HgCb group (27.4 nM), which returned close to control values in the 50 µM HgCh group 
(9.3 nM). 
Examination of transporter density (Bmax) values reflected the changes that were 
observed in the LOH assays. Control density of 49.7 pmol/mg protein was similar to 
observed Bmax values in the 5µM HgCh group (41.0 pmol/mg protein). Treatment with 
the highest concentration of HgCh (50 µM) resulted in a 69.1 % reduction in [3H] 
GBRl2935 binding (49.7 pmol/mgprotein to 15.4 pmol/mgprotein) (Figure 12). 
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Figure 12. Saturation of [3H] GBR-12935 binding to DAT in SK-N-SH cells. The cells were 
incubated with [3H] GBR-12935 an for a final concentration of I nM - 30 nM for 60 minutes at 
room temperature. Non-specific binding was determined in the presence of 5 µM GBR-12909. 
Data expressed as pmol of [3 H] G BR-12935 bound per mg of protein from one experiment 
perfonned in duplicate. Bmax values determined from these experiments for control, SµM HgCl2, 
and 50 µM HgCl2 are 49. 7, 41.0, and 15.4 pmol/ mg protein, respectively. 
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V. SUMMARY AND DISCUSSION 
V.A .. ~·11111mm:1· <?( Research Findings 
The main thrust for this research was to investigate how subtoxic concentrations 
of mercury aftected normal functional, cellular and phannacological aspects of neuronal 
cells~ specifically the SK-N-SH cell line. The functional studies focused on the dopamine 
transporter due to the fact that it's main substrate, dopamine, has been linked to 
neurotoxicity through contributions to oxidative stress, mainly production of reactive 
metabolites. The cellular studies defined cell viability after mercury treatment by 
measuring the activity oflactate dehydrogenase and caspase, enzymes associated with 
two different methods of cell death, necrosis and apoptosis, respectively. The 
pharmacological studies were employed to detennine the affinity of dopamine for the 
dopamine transporters found in SK-N-SH cells as well as the density of transporters. The 
overall findings from this project reveal that subtoxic concentrations of mercury do 
indeed produce functional, cellular and pharmacological changes in neuroblastoma cells, 
resulting in cell damage and/or cell death. 
VA. 1. Functional Studies 
There were three types of experiments run for the portion of the project focused 
on dopamine uptake: treatments incubated in assay buffer (refer to section 111.A.3), 
treatments incubated in growth medium, and comparisons between treatments incubated 
in assay buffer and ascorbate-free assay buffer. For the 'in buffer' studies, SK-N-SH 
eel ls were exposed to mercury concentrations ranging from I nM - I 00 µM HgCli in the 
presence of assay buffer for I to 6h at room temperature. The 'in media' studies looked 
at cells exposed to mercury concentrations ranging from 100 nM- I mM HgCl2 in the 
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presence of media for 1 to 48h at 37°C. The incubation temperature for the 'in media' 
studies differed in order to maintain the cells during longer treatment periods. The 
comparison studies that examined the effects of ascorbic acid in the assay buffer focused 
on 1 .. 10 .. and 100 ~1M HgCb concentrations incubated for 6h also at room temperature. 
The rationale for different assay conditions was to assess whether the more complex 
complete RPMI-1640 would interfere with the actions ofHgCl2. 
The interaction between time and concentration noted in the uptake measured at I 
and 3h may be caused by the initial action of the toxicant interacting with various cellular 
components .. resulting in functional changes, but which are insufficient to prevent 
dopamine transport. The minimal effect ofmicromolar mercury concentrations on 
dopamine uptake during the 6h exposure period reflects a compensation mechanism 
where the toxic action has temporarily stopped. It is also important to note that the 
uptake data collected for experiments incubated in the assay buffer showed very little 
change in respect to control values, which suggests that certain components of the assay 
buffer may be attenuating damage to the cells or production of species that cause 
oxidative stress. 
Prolonged exposure (> 6h) appears to allow for mercury to accumulate in the 
cells, resulting in cell damage and/or cell death. The uptake studies performed in the 
growth medium for longer periods of time demonstrate this proposed explanation. The 
data illustrate an extreme increase in [3H] dopamine uptake when treated with l O µM 
HgCli, followed by a severe drop in uptake. This may be a result of an overloaded 
dopamine turnover system that can no longer compensate for all the 'free' dopamine 
located in the synapse., which when metabolized can lead to the production of damaging 
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hydroxides. The fact that dopamine uptake does decrease when the cells are treated in 
the growth medium supports the idea that the composition of the media differs from that 
of the assay buffer in that it does not contain as many (if any at all) neuroprotective 
agents. 
The ex peri men ts that compared incubation in the assay buffer to incubation in a 
modi fled assay buffer lacking ascorbic acid showed a significant difference of [3H] 
dopamine uptake measured. Although the cells were exposed to the same concentrations 
of mercury ( 1 .. 1 0 .. l 00 µM HgCh), those incubated in the assay buffer maintained uptake 
values which were similar to control while those incubated in the ascorbate-free assay 
buffer showed a decrease in dopamine uptake between 10 µMand I 00 µM HgCli 
treatments. Perhaps the severe drop in dopamine uptake represents a toxicity threshold 
exhibited by the cells when treated in assay buffer without ascorbate. This difference in 
dopamine uptake also depicts the potency of ascorbic acid as an antioxidant, which can 
conceivably bind to the reactive oxidative species and prevent damage to the transporter 
for the samples run in the unadulterated assay buffer. 
V.A.2. Cellular Studies: Initiation of Necrotic or Apoptotic Mechanisms 
The cellular studies, which focused on enzymatic activity, LDH and caspase 
assays respectively., were used to assess cytotoxicity at different mercury concentrations. 
SK-N-SH cells were treated with 5 and 50 µM HgC12 for a 24h period in both media and 
assay buffer. 
The LOH assay revealed an effect of concentration; as the concentration of 
mercury increases, the amount of LDH release also increases. One can infer that LOH 
release follows a stepwise progression as the concentration of mercury increases until the 
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cells arc completely obliterated and LDH release plateaus. The assay for caspase activity 
showed a decrease with the 5 µM HgCh treatment, with no change in the data for the 50 
µM HgCl2 treatment. The lack of increase in caspase 3/7 activity compared to controls 
suggests apoptosis is not involved in the observed changes in DAT activity. Therefore 
mercury docs not induce apoptotic cell death at these concentrations. The data from the 
LDH and caspase assays indicate that when cells are treated with low levels of mercury 
(5 and 50 ~tM HgC12) in the presence of media, the cells are dying, but not by apoptotic 
mechanisms. 
V.A.3. Pharmacological Studies 
To complement the characterization of the DAT inhibition by HgCh, the 
interaction of HgCl2 with the DAT was examined using binding studies to address 
pharmacological changes in the treated cells. Similar to the cellular studies, SK-N-SH 
cells were treated with 5 and 50 µM HgCh for a 24h period at 37°C in the growth 
medium. 
The data from the binding studies showed changes in both the affinity and density 
of the dopamine transporters when SK-N-SH cells were treated with low-level mercury 
concentrations. When the cells were treated with 5 µM HgCh, the affinity of [3H] GBR-
12935 for DAT decreased four-fold, while there was no effect with 50 µM HgCh. The 
shift to lower affinity means the transporter is moving substrate (DA) at a high capacity 
and DA is able to freely diffuse into the cells, possibly reflecting the increase in DA 
uptake noted with 10 µM HgCh treatments. The changes in transporter density occurred 
with the 50 µM HgCh treatments but not the 5 µM HgCii group; decreasing transporter 
density by over 50%. This corresponds to the differences in LOH release noted earlier; 
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while the transporter density decreases and transport sites are being lost, LDH release 
increases due to toxicity brought on by an incapacitated dopamine turnover system. 
VB. Discussion 
J/:B. /. ( '/wracterization of the Dopamine Transporter Using GBR-12909 and Mazindol 
The data collected during the characterization studies supported the previous 
finding that GBR-12909 is a more selective inhibitor of the DAT. In order to 
differentiate whether the labeled dopamine is being taken up through the dopamine or 
norepinephrine transporters located on the cells, this selective inhibitor was paired up 
with one of the more nonselective DAT inhibitors, mazindol. The amount of dopamine 
uptake measured in the cells treated with GBR-12909 represents the amount of labeled 
dopamine that entered via DAT compared to control values while the amount of 
dopamine uptake measured in the cells treated with mazindol represents the amount of 
labeled dopamine that entered via DAT and NET compared to control values. By 
subtracting the uptake measured with mazindol from total uptake (control values) 
accounts for dopamine entering through DAT and NET. A further step of subtracting out 
the uptake measured with GBR-12909 from that value isolates the amount of dopamine 
that was taken up through DAT. 
V. B. 2. Measuring [3 HJ Dopamine Uptake After Toxin (Hg2+) Exposure 
The data from these functional studies suggest that the toxicity of mercury 
appears to be more concentration-dependent than time-dependent, even at lower 
concentrations. The observation that as the mercury concentration increases, the amount 
of dopamine uptake decreases implies that exposure to low levels of mercury can result in 
consequential effects on dopamine transport. Since the dopamine transporter is the 
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primary compensatory mechanism that regulates extracellular dopamine concentrations 
and maintains the homeostasis of presynaptic function in dopaminergic neurons (Torres, 
et aL 2003 ) .. any modifications in dopamine transport has the potential to interfere with 
normal dopaminergic function. 
The work of Chen and associates (2000) found that substrate uptake by DAT is a 
highly temperature-dependent active transport process. This lends support to the "All or 
Nothing"" phenomenon noted in the data where mercury treatments were carried out in the 
growth medium at 37°C .. which was not apparent in the data where mercury treatments 
were performed in assay buffer (refer to section III.A.3) at room temperature. The 
sudden decrease in dopamine uptake for HgCli concentrations greater than 100 µM for 
the "in media" studies may be resultant of the higher temperature increasing the 
production of free radicals, possibly accelerating the dysfunction of DAT. The observed 
differences in dopamine uptake between the media and assay buffer experiments could 
also be related to the specific components of each solution and how they may react in 
oxidative environments. 
As previously mentioned, when uptake assays were conducted in the media, 
dopamine uptake was virtually abolished following a 3-fold increase in uptake observed 
at 10 µM HgCh. It has been suggested that one reason levels of dopamine ( quantitated 
by [3H] DA uptake) have been shown to increase after administration ofHgCh may be 
due to the toxic metal's mechanism of action on various aspects of neuronal function; 
including release of neurotransmitter, reuptake and transporter systems (Faro, et al., 
2001 ). The fact that amounts of dopamine uptake did not fluctuate over time (1, 6 .. and 
24 h) with 10 µM treatments .. but only changed as the concentration of mercury increased 
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provides evidence that the SK-N-SH cell line may exhibit a toxicity threshold between I 0 
and I 00 µM HgCb. Kim and Sharma (2004) found an EC50 value of approximately 70 
µM of HgC12 in their work with BALB/c macrophage cells, which means this 
concentration of mercury resulted in 50% cell death. This also lends support to the 
severe change in dopamine uptake between 10- 100 µM HgCh noted in the data 
collected. 
The increase in dopamine uptake at 10 µM HgCh treatments performed in the 
growth medium may be indicative of an upregulation of the dopamine transporter. This 
could be due to insertion of reserve or "spare" DAT and not necessarily new transporter 
proteins .. which would take longer than 24 hours to synthesize and insert into the 
membrane. Our data suggests that upregulation did not occur as indicated by no changed 
in Bmax· Increased uptake may reflect an increase in·dopamine release; in order to 
compensate for the higher levels of extracellular dopamine in the synaptic space, the cells 
may increase., or upregulate the number of transporters to take up more dopamine. Wu, 
Coffey and Reith ( 1997) observed Hg2+ to have a biphasic effect on both [3H] mazindol 
and [3H] WIN 35.,428 binding to the dopamine transporter; with a stimulatory component 
in the low micromolar range and a strongly inhibitory component at 30-100 µM in glioma 
cells expressing human DAT. If the number of binding sites decreases, then the number 
of transporters must also decrease. The data from the experiments performed in the 
growth medium show a similar biphasic pattern with a decrease in dopamine uptake at 
higher mercury concentrations. Perhaps the decrease is due to depletion in the number of 
DAT" a suggestion that is supported by this data, which demonstrated a 70% reduction in 
the Bmax of DAT. 
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Due to interaction of metal ions with sulfhydryl groups in the dopamine 
transporter. both dopamine uptake and binding of uptake inhibitors are changed when 
exposed to metal ions ( Ferrer and Javitch, 1998), especially with mercury because of its 
high affinity for sultl1ydryl groups. Previous research has suggested sulfhydryl groups 
play a key role in binding to the dopamine uptake complex (Richfield, 1993). If reduced 
sulf11ydryl groups (bound to electrophiles) have the ability to alter the affinity states of 
uptake inhibitor drugs or transmitter for DAT (Richfield, I 993), the acute decrease in 
uptake noted in the data for higher mercury concentrations could be attributed to a 
reduced atlinity of dopamine for the DAT. 
Sultl1ydryl groups have also been associated with confonnational changes in the 
dopamine transporter protein, which has been shown to affect both inward and outward 
DA transport (Chen. et al., 2000). The human dopamine transporter contains 13 cysteine 
residues (Torres .. et al., 2003); therefore providing 13 potential sites for mercury to bind 
(refer to Figure I) and alter the confonnation of the transporter. In reference to the 
bimodal pattern observed, the stimulatory effect of Hg2+ has been attributed to a 
conformational change in the DAT caused by creating disulfide linkages between two 
intra- or intern1olecular cysteine sulfhydryl groups (Schweri, I 994), whereas the 
inhibitory effect probably involves recognition of cysteine -SH groups intimately linked 
with the binding sites for uptake blockers (Wu, et al., 1997). According to Torres, 
Gainetdinov and Caron (2003), a cysteine residue located in the third intracellular loop of 
DAT was found to be more reactive to thiol-modifying agents like mercury during 
uptake'I implying that this residue participates in a conformational reorganization of DAT 
during substrate translocation, ultimately impeding DAT function. Perhaps the extreme 
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increase in dopamine uptake noted with 1 OµM treatment is resultant from mercury 
binding to sulfhydryl groups, altering the conformation of DAT such that inward 
transport of extracellular dopamine has stopped and in order to remove excess dopamine 
from the synapse, the cells must upregulate DAT expression. The severe decrease in 
dopamine uptake observed at higher concentrations could' be a consequence of the 
dopamine uptake system simply becoming overloaded by excess dopamine and causing 
complete cessation of transporter function. Mercury's ability to alter DAT conformation 
substantiates the biphasic response demonstrated by the data. 
The work of Hussain and colleagues (1997) concluded that exposure to mercury 
(HgCh) decreased SOD~ Cu/Zn-SOD and Mn-SOD activity; all of which play a role in 
the cellular defense mechanisms that work to prevent accumulation of reactive oxygen 
species brought on by oxidative stress. The differences in dopamine uptake between 
experiments run in assay buffer and experiments run in ascorbate-free assay buffer (as 
seen in Figure 8) suggests that the presence of ascorbic acid, a potent antioxidant, may 
attenuate the effects of mercury-induced oxidative ·stress. Similarly, previous research 
found that other antioxidants, DPPD and Trolox, were not effective in the prevention of 
HgCl2-induced cell death (Lee, et al., 2001). Although antioxidants may prolong the life 
of the cell by binding to free radicals and alleviating oxidative stress, they have not been 
proven to ultimately prevent cell death. 
VB. 3. Cytotoxicity and Cell Viability 
In order to relate the changes observed in dopamine uptake to overall cellular 
function, the concentrations of mercury (5 µM and 50 µM ) used for the LDH and 
caspase experiments were chosen because these concentrations surround the increase in 
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dopamine uptake noted with the 10 µM HgC12 treatments. The cells were incubated for 
24h in the growth medium. similar to conditions in the uptake studies, but also in the 
assay buffer to examine any variation in cellular function when exposed to mercury in 
different solutions. 
I .. actate dchydrogenase is a cytosolic enzyme often used as an indicator of 
toxicity .. specifically defining cell death (Hodgson and Smart, 2001). LDH release has 
been closely associated with several cellular properties, including membrane stability, 
transporter channel function and other metabolic activities. According to Allen and 
Rushton ( 1994 ) .. in vitro release of LDH from cells provides an accurate measure of cell 
membrane integrity and cell viability. Through colorimetric or radioactive assays, the 
measurement of lactate dehydrogenase released from cells into the medium has been 
established as a useful parameter affected after toxic cellular events (Reich!, et al., 2001), 
such as incubation with a toxic oxidative metal, like mercury. As purported by previous 
research .. an increase in the LDH release may reflect a wide spectrum of intracellular or 
membrane influences (Reichl, et al., 2001). For these experiments, an increase in LDH 
( compared to control values) is indicative of cell death subsequent to mercury treatment. 
The data from the LDH experiments where the growth medium was the solution 
used for the incubation period showed a similar relationship concerning cellular function 
between absorbance and concentration that was observed between dopamine uptake and 
concentration. As the concentration of mercury treatment increased, the amount of 
absorbance increased .. which equates to the amount ofLDH increased, indicating a loss of 
plasma membrane integrity and/or cell death. A loss of cellular function was suggested 
by a decrease in dopamine uptake as the concentration of mercury treatments increased. 
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In their research. Lee. Ha and Kim (2002) found HgC}i had concentration-dependent 
effects on cytotox ici ty in glioma cells. Reichl and colleagues (200 I) observed a 
comparable phenomenon in their work with lung cells; finding an increase in LDH 
release after exposure to HgCh when compared to control values. 
The data from this assay demonstrated a significant increase in LOH release for 
SK-N-SH cells exposed to 50 µM HgCli for 24h compared to control values, but 
statistical analysis (Dunnetf s Multiple Comparison Test) failed to find a significant 
difference between the LOH release measured from cells treated with 5 µM HgCb for 
24h and control values. In previous work, mercury compounds, including HgCl2, were 
found to increase LDH release, at concentrations greater than IO µM for 8 and 24 hours 
exposure periods in lung cells (Walther, et al., 2002), again suggesting that the cells may 
exhibit a toxicity threshold, and once surpassed, resl:llts in cell death. This conclusion 
corroborates the data gathered from the LDH assay; finding significant LOH release at 
higher concentrations (50 µM HgCh) but not at lower concentrations (5 µM HgCh) 
compared to control levels. 
V. B. 4. Initiation of Apoptotic Mechanisms: Caspase-3 and -7 Detection 
The various stages associated with chemically induced apoptosis are triggered by 
caspase cascades (Hodgson and Smart, 2001), which initiate the sequential dysregulation 
of mitochondrial function, resulting in cell shrinkage and nuclear fragmentation; 
ultimately leading to the 'systematic dismantling' of the cell. Caspases have been 
classified as a family of aspartate-specific cysteine proteases, which are key effectors 
responsible for many morphological and biochemical changes in apoptosis (Kim and 
Sharma .. 2004 ). Due to the fact that activated caspase enzymes participate in the 
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proteolyt ic cleavage events found in dying cells, caspase-3 activation has been deemed an 
essential step to actuate the cascade of apoptotic processes (Kim and Sharma, 2004 ). 
This enzyme is also responsible for activating DNA fragmentation factor, resulting in 
frac tured DNA (Kim and Sharma, 2004), another aspect leading to cellular dysfunction. 
Although statistical analysis sho,ved a significant difference between relative 
/7uoresccncc measured for cells treated with 5 µM HgCh and concrol values, there n-a.s 
not a marked difference between the average RFU values for both groups. Therefore, 
mercury-induced cytotoxicity for these concentrations does not appear to be from 
apopto tic mechanisms. The data presented by Kim and Sharma (2004) reported an ECso 
value of 81 . I ~tM Hg Ch for caspase-3 activity when murine macrophage cells were 
incubated with mercury concentrations (20- 150 µM) for 24h. Since the mercury 
concentrations examined during this study did not exceed the ECso value, this may serve 
as an explanation as to why little increase in relative fluorescence was noted. This 
suggests that larger concentrations of mercury are required to induce apoptotic cell death. 
The work of Yang and colleagues (2002) found that SK-N-SH cells cultured in a 
s imilar medium (RPMI 1640 supplemented wi th 10% heat-inactivated FBS) for longer 
periods of time (5 days vs. I day) exhibited a 6-fold increase in caspase-3 activity. For 
the LDH and caspase studies, a span of four days passed from when the cells were plated 
out to when they were treated with mercury, followed by an additional 24h incubation 
period and another 8h required by the modified caspase 3/7 protocol. Perhaps the lack of 
change in RFU between control values and 50 ~tM HgCb treatments is due to the 
different culture periods; since there is nonnally a low level of caspase activity in the 
cells, and a prolonged culture period may also increase caspase activity, any further 
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caspase activity resultant of mercury-induced apoptosis may not be detectable due to. 
n uorescence saturation. 
1: B. 5. BindinR Studies: A./linity and Density of the Dopamine Transporter 
These data represent the first partial characterization of [3H] GBRI2935 binding 
to DAT in SK-N-SH cells. The affinity of [3H] GBR12935 (6.5 nM) resembled the 
aninity of (3H) GBR I 2935 (5.5 nM) previously reported in mammalian tissue (Andersen, 
1987). Surprisingly. this is contrary to previous beliefs that the predominant 
catecholamine transport system in SK-N-SH is NET. This would suggest that prevalence 
of DAT is actually considerable higher than what was first determined using transporter 
message expression. The changes that were observed in transporter density paralleled the 
changes that were observed in LOH release and loss of [3H) dopamine uptake in the 50 
~tM Hg Cb group fo llowing 24 hour exposure; i.e., cells die, leading to loss of DAT. The 
uptake of dopamine was previously determined to be unchanged in the 5 µM HgCl2 
group at 24 hours. a finding substantiated by the saturation data with minimal changes in 
the Bmax of [3H] GBR I 2935 binding. Interestingly, there is a reduction in affinity in this 
group. Collectively. these data suggest that a reduction in affinity with no observed loss 
in dopamine uptake may be a prelude to the loss of dopamine uptake in functional studies 
and loss of [3H] GBR 12935 binding sites in the saturation analysis. Additional work is 
needed to further the pharmacological characterization of dopamine uptake sites in SK-
N-S H cells. 
V. C. Further Research 
ruture work includes examination of intra- and extracellular events that may lead 
to a decline in neuronal function following mercury exposure. These events could be 
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oxidative stress. changes in intracellular signaling systems and potential damage to cell 
surface proteins and lipids. 
Oxidative stress can be quantified using dichlorofluorescein assay (Wang and 
Joseph. I 999): where reactive oxygen species present in the sample oxidize 
nonfluorescent dichlorofluorescein to produce the extreniely fluorescent 
dichlorotluorescein. By employing this experiment, one can determine whether the 
cytotoxicity induced by mercury is associated with oxidative stress or due to other cell 
damaging mechanisms. Microscopic examination of the cells post-mercury treatment 
may allow for specific cellular changes to the membrane and nuclear material to be 
charted over time. noting especially chromatin and cell condensation, blebbing, DNA 
fragmentation , lysosomal degradation, lysis, etc. This information may provide support 
to the data from the uptake studies, which suggest subtle cellular changes may be 
occurring before DAT function is affected. 
Previous research using neuroblastoma and glial cells concluded that lower and 
intermediate metal concentrations led to inhibition of neurospecific endpoints, defined by 
neuron-specific enolase (NSE) as a neuronal marker and glia-specific beta-S 100 protein 
as a glial marker, while no changes were noted concerning LDH release (Huang, et al., 
1993 ). These findings suggest that although release of LOH is indicative of overall 
cytotoxic effects, these nerve-specific changes may serve as a more sensitive index of 
neurotoxicity in similar cell lines. According to Huang and colleagues (1993), in a neural 
cell line, the most sensitive endpoints to neurotoxic insults are neurospecific, because 
while non-specific cellular endpoints only reflect the generic functions required for cell 
viability, by definition, tissue- or organ-specific endpoints hold special relevance to that 
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particular cell or tissue type. Focusing on neurospecific biomarkers may provide a more 
complete understanding of how mercury affects neuronal function with respect to the 
dopaminergic neurons in the substantia nigra and what intem1ediary changes are 
occurring to initiate toxic mechanisms in these cells. 
Supplementary studies to examine potential temperature- and growth 
medium/assay buffer (refer to section 111.A.3) composition-dependent effects on 
dopami ne uptake could be performed to more closely reflect what would be seen in vivo. 
Parallel in vivo studies using striatal synaptosomes from rats where mercury is 
administered via iqjection or implantation of a mini-pump would also offer data 
concerning functiona l, cellular and phamrncological effects comparing mercury treatment 
and control values. These experiments may help to better gauge the threat of mercury 
contributing to the progression of neurodegenerative disease. In vivo studies could 
additionally be used to directly target the possible link between mercury and A lzheimer's 
disease. After exposing the rats to low concentrations of mercury, tests could be 
performed to measure the quantities of P-amyloid peptide or phosphorylated tau protein 
in conj unction with apolipoprotein genotyping to investigate whether the combination of 
homozygous e.i phenotype and expoSure to mercury increases the animal's susceptibility 
Lo AD. In vivo experiments would also provide an opportunity to evaluate the potential 
. t ' f antioxidants nnd possible chelators after mercury treatments protccl1 ve ac rnn o · 
V. D. ( 'unc/usions 
• 
1 (l\\\\\W \n ake are concentration-The data suggest that HgCl2 effects on oopmn,,~ ,i;; 
dependent and not time-dependent. The observation cha r reductions in dopamine 
uptake are concentration-dependent could indicate;' that exposure to low amounts 
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• 
• 
• 
of mercury could result in robust effects on DA transport. Any number of 
changes in DA transport may have the capacity to initiate a cascade of biological 
events leading to cell damage and/or cell death. 
Examination of LDH and caspase enzymatic activity revealed that lower 
concentrations of mercury do indeed result in cytotoxicity. The increase in LDH 
release noted with the 50 µM HgCli treatment and lack of increase in caspase 
activity suggests that apoptosis does not play a role in the observed changes in 
DA transport. Instead, the data demonstrate that mercury-induced cytotoxicity is 
more a result of necrotic mechanisms, due the overall trauma sustained by treated 
cells. 
Although previous research has suggested that the SK-N-SH cell line expresses 
more NET, the data from the binding studies indicate these cells have a high 
density of dopaminergic sites (49.7 pmol/ mg protein). The density of DAT 
decreases as the concentration of mercury increases; the data reveal a 70% 
decrease in density for the higher concentration (50 µM HgC}i). 
Mercury treatment also resulted in pharmacological changes in radioligand 
binding to the DAT. The shift to lower affinity upon treatment with 5 µM HgCh 
switches the DAT to a high-capacity transport system, allowing more DA to cross 
into the cell. The shift back to high affinity observed with 50 µM HgCh may be 
explained by the significant reduction in transporter density, leaving only the 
resilient cells, which express the high affinity transporter. 
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